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  Arenaviruses are globally distributed, negative-sense, single-stranded RNA viruses 
which persist in specific rodent host species.  Of the 32 known arenaviruses, 10 have 
been associated with human disease.  Of these, Lassa, Junín, Machupo, Guanarito, and 
Sabia viruses cause severe hemorrhagic fevers. The only current option for the treatment 
of arenavirus infection is the off-label use of ribavirin.  However, ribavirin is associated 
with severe side effects.  Clearly, there exists a need for the study of arenavirus biology 
and of novel drugs for the treatment of arenaviral infection.  My work focused on two 
attractive targets for inhibition of infection: the arenaviral RNA-dependent RNA 
polymerase, to block replication of the viral genome, and the arenaviral envelope 
glycoprotein (GPC), to prevent delivery of the viral genome to the cytosol. We showed 
that the novel purine analogue, T-705, is effective at inhibiting the replication of highly 
pathogenic arenaviruses in vitro.  Further, we showed that T-705 specifically blocks viral 
transcription without significantly reducing cellular transcription activity.  We also 
explored the interactions between the SSP and G2 subunits within GPC.  We 
demonstrated that the first transmembrane region of  SSP is a functional subdomain and 
that the interactions between this region and the transmembrane region of G2 are 
essential to fusion activity.  Further, we demonstrated that residues in this subdomain are 
key to drug sensitivity.  We also worked to characterize the arrangement between the 
transmembrane regions using cysteine-scanning mutagenesis and we engineered a 
construct linking the first transmembrane region of SSP to the transmembrane region of 
G2 to serve as a potential model for studying the interactions between these two regions.  
iii 
Acknowledgments 
I would like to take the opportunity to thank those that supported me and during 
my time at the University of Montana.  Obviously, I need to thank Jack Nunberg, for his 
time and work as my advisor.  I also need to express my appreciation for the other 
members of my laboratory who assisted me on countless occasions: Jo York, Nick Baird, 
Sundaresh Shankar, Celestine Thomas, Hedi Casquilo-Gray, and Donna Twedt.  I am 
grateful to my committee members, Steve Lodmell, Scott Wetzel, Brent Ryckman, and 
Keith Parker, for all of their time and efforts throughout my studies.  In particular, I am 
especially indebted to Steve and Scott for always be available to listen and address my 
concerns despite their busy schedules.   
 
 I want to express my gratitude to my husband, Paul, and to my friends Sundaresh 
Shankar, Indu Warrier, Melissa and Greg Hargreaves, Wes Samson, Tammy Ravas, and 
my former boss Dawn Bowles.  I think there are many ups and downs for any graduate 
student, but without their kindness and emotional support, my road would have been a lot 
bumpier.
iv 
Table of Contents              Page 
Abstract                                                             ii 
Acknowledgements                                                    iii 
List of Abbreviations Used                                            v 
 
List of figures                                                     vii 
 
Chapter 1: Introduction                                               1 
 
A. The Arenavirus Family                                              1 
B. Overview of the virus life cycle                                   5 
C. Inhibiting replication                                             7 
D. The unique Arenaviral GPC and Inhibition of Fusion                11 
E. Hypotheses and Significance                                       15 
  
 
Chapter 2: T-705 (Favipiravir) Inhibition of Arenavirus Replication  
in Cell Culture                                                      18  
 
A. Introduction                                                      19 
B. Materials and Methods                                             20 
C. Results                                                           25 
D. Discussion                                                        32 
 
Chapter 3: Dissection of the role of the stable signal peptide of  
the arenavirus envelope glycoprotein in membrane fusion              35 
 
A. Introduction                                                      36 
B. Materials and Methods                                             39 
C. Results and Discussion                                            42  
D. Conclusions                                                       58 
 
Chapter 4: Engineering of a Potential Model for the Transmembrane  
Interactions within the Trimeric Arenaviral Glycoprotein Complex     60 
 
A. Introduction                                                      60 
B. Methods                                                           61 
C. Results                                                           64 
D. Discussion                                                        69 
 
Chapter 5: Cysteine Scanning Mutagenesis and Cross-linking within  
the G2 Transmembrane Domain                                          71 
 
A. Introduction                                                      71 
B. Methods                                                           73 
C. Results and Discussion                                            76 
 
Chapter 6: Conclusions and Future Directions                         82 
 
Works Cited                                                          89 
 
v 




 - bis(sulfosuccinimidyl)suberate        
CC50 – concentration of drug that yields 50% cytotoxicity 
CHAPS - 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CMV – cytomegalovirus 
CuP – copper(II)-(1,10 phenanthroline)3 
DAPI - 4',6-diamidino-2-phenylindole 
DDM - Lauryl-β-D-maltoside 
DPC - n-dodecylphosphocholine,  
EC50 – concentration of drug that yields 50% effectiveness 
EPR – electron paramagnetic resonance 
FITC - Fluorescein isothiocyanate  
fLuc – firefly luciferase 
GPC – arenaviral envelope glycoprotein 
GnHCl - guanidine hydrochloride 
GTOV – Guanarito virus 
GTP – guanosine triphosphate 
G1 – receptor binding subunit of GPC 
G2 – fusion subunit of GPC 
HF -  hemorrhagic fever 
IMPDH – inosine monophosphate dehydrogenase  
IP - immunoprecipitations 
IMP – inosine monophosphate 
JGPC- Junín GPC 
JCD4A – JGPC construct in which SSP is replaced by the signal peptide from human 
cluster of differentiation 4 
JUNV – Junín virus 
L – arenaviral RNA-dependent RNA-polymerase 
LASV – Lassa virus 
LCMV – Lymphocytic choriomeningitis virus 
MACV – Machupo virus 
MG – minigenome cassette 
MoMuLV - Moloney murine leukemia virus 
NP – arenaviral nucleoprotein 
PAGE – polyacrylamide gel electrophoresis 
OW – old world 
PBS – phosphate buffered saline 
PFA - Paraformaldehyde  
POPC- palmitoyloleoyl phosphatidylcholine 
POPE- palmitoyloleoyl phosphatidylethanolamine 
POPG- palmitoyloleoyl phosphatidylglycerol 
NW – new world 
RdRp - RNA-dependent RNA-polymerase 
rLuc – Renilla luciferase 
RT – room temperature 
vi 
SEC – size exclusion chromatography 
SDS – Sodium dodecyl sulfate 
Spep – S-peptide  
SSP – stable signal peptide, subunit of GPC  
TM – transmembrane 
TM1 – N-terminal transmembrane region in SSP 
TM2 - C-terminal transmembrane region in SSP 
TMCON – transmembrane construct 
Tris – trisaminomethane 
TX-100 -  Triton X-100 (Polyethylene glycol tert-octylphenyl ether) 
T-705 – favipiravir 
T-705RTP - T-705 ribofuranosyl triphosphate    
wt- wild type 
XMP – xanthosine monophosphate 
VHF – viral hemorrhagic fever 
Z – arenaviral matrix protein 
ZBD – zinc binding domain 
vii 
List of Figures and Tables                                      Page 
 
Figure 1: The Global Distribution of Arenaviruses                     2  
Figure 2: Arenavirus Structure and Lifecycle                          7 
Figure 3: Structures of active forms of Ribavirin and T-705           9 
Figure 4: Ribavirin disrupts GTP pools                               10 
Figure 5: Mechanism of Membrane Fusion                               12 
Figure 6: GPC schematic and proposed subunit organization            13 
Figure 7: T-705 inhibition of highly pathogenic arenaviruses in  
Vero E6 cells                                                        26 
Figure 8: Time of addition of T-705 to arenavirus-infected Vero 
E6 cells                                                             27 
Figure 9: Reversal of T-705 antiarenavirus activity in Vero cells 
infected with TCRV or JUNV-C                                         29 
Figure 10: T-705 inhibition of LCMV replicon system                  30 
Figure 11: Reversal of T-705 LCMV replicon inhibition                31 
Figure 12: GPC open reading frame and subunit organization, and 
comparison of JUNV and LASV SSP amino acid sequences                 37 
Figure 13: Membrane fusion activity of JUNV and LASV hybrids and 
TM1 mutants                                                          43 
Figure 14: JUNV and LASV hybrid GPCs are properly assembled, 
proteolytically matured, and transported to the cell surface         45 
Figure 15: JUNV GPCs containing chimeric SSPs are properly  
assembled and proteolytically matured                                48 
Figure 16: Helical-wheel projections of the amphipathic TM1 of  
JUNV and LASV SSP                                                    53 
Figure 17: Mutations in SSP TM1 affect sensitivity to small- 
molecule fusion inhibitors                                           57 
Figure 18: Schematic and structural model of TMCON                   61 
viii 
Figure 19: Purification of TMCON                                     66 
Figure 20: Oligomeric state of TMCON                                 67 
Figure 21: TMCON associates weakly with GPC                          69 
Figure 22: Possible arrangement of TM domains in GPC  
(top-down view)                                                      72 
Figure 23: Cysteine mutations are well tolerated                     77  
Figure 24: Oxidative Crosslinking                                    80 
Table 1: In vitro inhibitory effects of T-705 and ribavirin  
against VHF arenaviruses
a 
                                            26 
Table 2: JUNV GPC-mediated fusion IC
50
s                               57 
















Chapter 1: Introduction 
1a. The Arenavirus Family  
The Arenaviridae family of viruses comprises one genus, Arenavirus, which can be 
divided phylogenetically into two serocomplexes: the Old World (OW), or the Lassa-
Lymphocytic choriomeningitis group, and New World (NW) group.  Viruses from each 
serocomplex have been identified as causative agents of viral hemorrhagic fevers (VHF) 
(McLay et al., 2013). The NW viruses can be further divided into three clades (A, B, C) 
with all of the NW viruses capable of causing VHF clustered within clade B (Emonet et 
al., 2009).  These include the Junín (JUNV), Guanarito (GTOV) and Machupo (MACV) 
viruses (Buchmeier et al., 2007).  Arenaviruses are each harbored primarily within one 
major reservoir from the rodent family Muridae, with the possible exception of  the NW 
Tacaribe virus that been found in bats (Charrel et al., 2011; Salazar-Bravo et al., 2002).  
The association of virus and host limits the geographic distribution of each virus to the 
range of its host.  The prototypic OW Lymphocytic choriomeningitis virus (LCMV), 
which persists in the common house mouse, Mus musculus, is the only arenavirus found 
globally (figure 1). Of the arenaviruses, LCMV, Lassa virus (LASV) and JUNV are of 
particular significance to my research. LCMV, first isolated 1933, is the prototypic 
arenavirus and it has been extensively used as a model of arenaviral biology and 
infection.  It is reported that about 5% of humans are seropositive for LCMV (Emonet et 
al., 2009; Peters, 2006).  Generally not considered a public health threat as most acquired 
infections are asymptomatic, LCMV does cause serious infection in 
immunocompromised individuals and is an overlooked fetal teratogen (Barton et al., 
2002; McLay et al., 2013).   
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LASV is the causative agent of Lassa fever, first described in Nigeria in 1969.  
LASV is estimated to cause between 300,000–500,000 infections and 5000-6000 deaths 
annually throughout West Africa.  The highest incidence of disease has been reported in 
Mano River Union countries of Sierra Leone, Liberia, and Guinea.  (Khan et al., 2008; 
Russier et al., 2012).  Significantly, LASV has also been exported to North America and 
Europe several times by travelers (Ftika and Maltezou, 2013; Macher and Wolfe, 2006; 
Safronetz et al., 2010).  The natural reservoir of LASV is the ubiquitous rodent, 
Mastomys natalensis, which is found throughout sub-Saharan Africa (Ogbu et al., 2007).  
People most often become infected with LASV through either direct contact with infected 
rodents or inhalation of rodent excreta.   Those living in rural communities or areas with 
poor sanitation are most at risk.  Infection may then be passed between humans through 
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direct contact with bodily fluids or fomites.  The outcome of LASV infection varies from 
asymptomatic or mildly acute cases to severe disease and death.  The overall mortality 
rate for LASV infection is low, around 1%. Of those hospitalized for LASV infection, the 
mortality rate is 15%-20%.  Further, a significant number of Lassa fever survivors 
experience long-term neurological side effects such as deafness (30%) (Cummins D et 
al., 1990).  It is still unclear why some patients appear to recover from LASV and others 
develop VHF (Ogbu et al., 2007; Russier et al., 2012).   
JUNV, the causative agent of Argentine hemorrhagic fever, was first discovered 
and characterized in the 1950s (Parodi et al., 1958).  As with LASV, humans generally 
become infected through direct or indirect contact with the rodent reservoir, Calomys 
musculinus, though nosocomial spread is also possible.  The persons at highest risk are 
agricultural workers who have increased contact with C. musculinus. (Colebunders et al., 
2002; Enria et al., 2008; Radoshitzky et al., 2012).   It is estimated that most (80%) 
infections of JUNV result in disease.  Of these, the mortality rate is between 15% and 
30%.  Before the development and use of the JUNV vaccine strain Candid-1 in Argentina 
in the 1990s, JUNV caused between 300 and 1000 cases of VHF per year. Since then, the 
rate has dropped to between 30 and 50 infections every year (Ambrosio et al., 2011; 
Enria et al., 2008; Harrison et al., 1999).  Saliently, the region of endemic infection has 
been increased by 150,000km
2
 and there are now an estimated 5 million people at risk for 
infection (Ambrosio et al., 2011; Radoshitzky et al., 2012). 
VHFs caused by LASV and JUNV display similar symptoms. Reported 
incubation periods for LASV range from 3-21 days and 6-14 days for JUNV. Generally, 
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illness begins with non-specific signs: malaise, headache, fever, and muscle aches.  
Disease then progresses to petechial hemorrhage, edema, respiratory distress, shock, 
decreased platelets and white blood cells, and mucosal bleeding.  Liver dysfunction is 
more common in severe cases of Lassa fever than in VHF caused by NW viruses.  
Neurologic symptoms such as irritability, confusion, and tremors are much more 
common in JUNV infections.  Hemorrhage in LASV infections occurs in roughly 20% of 
patients, and is frequently localized to the gums.   In the case of JUNV infection, 
hemorrhage is more common, widespread, and severe.  (Cummins, 1991; Enria et al., 
2008; Khan et al., 2008; McLay et al., 2013; Ogbu et al., 2007). 
Treatment options for arenaviral infections are limited.  The Candid-1 attenuated 
vaccine is not FDA-licensed and there are no vaccines available for LASV or any other 
pathogenic arenavirus.  Treatment of JUNV patients with donor serum from survivors has 
been successful in treating JUNV infection when administered within 8 days of onset of 
symptoms, (Enria et al., 2008; Harrison et al., 1999) but this has not been the case with 
LASV infection (Cummins, 1991).  The only currently available drug for the treatment of 
arenaviral infection is the off-label use of ribavirin.  This drug has been used to treat 
LASV and JUNV infections with success, if administered early in the course of infection.  
However, its use is associated with some severe side-effects, such as anemia (Cummins, 
1991; Damonte and Coto, 2002; Enria et al., 2008).   
Arenaviruses continue to be a significant public health threat.  The increase of 
human activity (agricultural or recreational) within the natural habitats of rodent 
reservoirs, in combination with ecological changes, has been linked to the spread of 
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known arenaviruses and the emergence of new arenaviral species in people (Ambrosio et 
al., 2011; Charrel et al., 2011).  Novel pathogenic arenaviruses are reported to emerge on 
average every 2-3 years (Pasquato et al., 2011).  Further, the repeated exportation of 
LASV to the western world demonstrates that these viruses are not just a threat to their 
endemic regions, but to the global community.  Additionally, the fact that the natural 
mode of infection is inhalation of rodent excreta raises the concern that these viruses 
maybe intentionally aerosolized for use as weapons.  These factors, combined with high 
mortality rates and the lack of treatment options, have led to the classification of Lassa, 
Junín, Machupo, and Guanarito viruses as Category A priority pathogens by the U.S. 
(NIAID,2011).    There is a clear need to study arenaviral biology to further our 
understanding of how these viruses cause infection and how we may develop antiviral 
drugs to interfere with the viral life cycle. 
1b. Viral Life Cycle Overview 
 Arenaviruses are pleomorphic enveloped viruses which contain a bi-segmented 
ambisense RNA genome.  The large genome segment encodes the RNA-dependent RNA 
polymerase (L) and the matrix protein (Z).  The small segment encodes the envelope 
glycoprotein (GPC) and the nucleoprotein (NP) (figure 2) (Emonet et al., 2009; Meyer et 
al., 2002). GPC is expressed as a trimer on the viral envelope.  It forms a spike that is 
composed of three non-covalently associated subunits, G1, G2, and a stable signal 
peptide (SSP).  The G1 subunit is the ‘head’ on the spike and provides the receptor-
binding function for the virus (Kunz et al., 2003).  OW viruses and clade C NW viruses 
use α-dystroglycan to bind to the cell surface while NW clade B viruses utilize transferrin 
receptor-1 (Cao et al., 1998; Kunz, 2009; Radoshitzky et al., 2007; Rojek et al., 2008).  
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G2 forms the ‘stalk’ and is responsible for membrane fusion.  SSP is a 58 amino acid 
peptide that spans the membrane twice, with both termini residing on the cytosolic face 
of the membrane (Agnihothram et al., 2007).  Its importance in the structure and function 
of GPC will be discussed at length below.  The non-lytic viral life-cycle is initiated when 
virus binds to the surface of the cell.  The virion is then endocytosed.  Unlike NW clade 
B arenaviruses, which  are endocytosed  in a clathrin-dependent fashion (Vela et al., 
2007), OW arenaviruses undergo an unusual endocytotic pathway independent of 
clathrin, caveolin, dynamin, and actin (Pasqual et al., 2011).  Although the pathways are 
distinct, delivery into the low-pH late-endosome is essential for entry by both NW and 
OW arenaviruses (Rojek et al., 2008).  As the endosome is acidified, a series of dramatic 
conformational changes in G2 takes place which leads to fusion of the viral envelope 
with the endosomal membrane.  This allows entry of the viral genome into the host 
cytosol, where viral replication occurs.  NP and L are necessary and sufficient for 
replication of the genome (Emonet et al., 2009).  As the host does not have an RdRp, the 
viral polymerase is an attractive target for antiviral strategies and has been shown to be 
sensitive to drugs such as the purine analogs ribavirin and T-705, which we have 
investigated in chapter 2.  Preventing access of the virus to the cytosol by blocking 
membrane fusion is another very attractive target in the viral life cycle.  Elucidating the 
precise structure of GPC and how it mediates membrane fusion will help us to better 
understand the biology of arenaviruses and potentially aid in the development of fusion 
inhibitors.  This is the focus of chapters 3-5.  
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1c. Inhibiting Replication 
The arenavirus RdRp transcribes and replicates the viral genome.  During 
transcription, the RdRp produces subgenomic mRNAs which terminate at the IGR (figure 
2A) (Conzelmann, 1996). In replicating the genome, the RdRp reads through the IGR and 
synthesizes uncapped, full-length genomic and anti-genomic viral RNAs.  NP associates 
with the viral RNA to form the nucleocapsid, the template for the RdRp (Fuller-Pace and 
Southern, 1988).  The 3’ terminus of both the L and S segments contains a conserved 
sequence of 19 nucleotides which base-pairs with an almost complementary sequence in 
8 
the 5’ terminus to form a panhandle.   This structure, and its sequence, are essential for 
forming a functional promoter for transcription and replication  (Perez and de la Torre, 
2003).   Together, the nucleocapsid and  the RdRp make up the viral ribonucleoprotein 
complex, the minimum requirement for genome replication (Lee et al., 2000).   We have 
taken advantage of this fact by using a minigenome system to study the activity of the 
RdRp.  This system, developed by collaborators in the de la Torre laboratory (Lee et al., 
2000), involves the use of an LCMV minigenome cassette (MG) co-transfected with 
plasmids coding for the viral polymerase  and the NP.  The MG plasmid contains the 
firefly luciferase gene in the antisense orientation flanked by the necessary noncoding 
segments from the LCMV S RNA (5’ UTR, IGR and the 3’ UTR) and is dependent upon 
the viral polymerase for expression of luciferase.   
To date, the only treatment available for arenaviral infections is the off-label use 
of ribavirin (1-beta-D-ribofuranosyl-1,2, 4-triazole-3-carboxamide), which is 
phosphorylated in the cell to its active form (figure 3A).  Ribavirin has been used to treat 
other viral infections such as chronic hepatitis C (Maag et al., 2001) and it has been used 
to treat Lassa victims with mixed results (Khan et al., 2008).  The mechanism of action of 
ribavirin is unclear and it may vary among different viruses. Ribavirin is known to act as 
an inhibitor of RNA-capping in vaccinia infections and to antagonize RdRp activity by 
competing with GTP during influenza replication (Graci and Cameron, 2006).   
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Ribavirin can base pair to both cytidine and uridine (figure 3A), and therefore has 
the potential to lead a virus to lethal mutagenesis, as demonstrated in its inhibition of 
poliovirus (Crotty et al., 2000),  LCMV (Moreno et al., 2011) and hepatitis C (Maag et 
al., 2001).  Ribavirin is also known to inhibit the enzyme inosine monophosphate 
dehydrogenase (IMPDH).  This enzyme catalyzes the synthesis of xanthosine-5'-
monophosphate, the precursor to guanosine-5'-monophosphate.  Therefore, inhibition of 
IMPDH disrupts guanosine triphosphate (GTP) pools (figure 4).  This reduction in 
available GTP has been implicated in the inhibition of flaviviruses, paramyxoviruses, 
nidoviruses, and LCMV (Kim and Lee, 2013; Leyssen et al., 2005; Moreno et al., 2011).  
It is likely that the strong inhibitory effect of ribavirin on arenaviral infection is due to the 
combined effects of simultaneously increasing the rate of mutagenesis in the viral 
genome and by reducing available GTP (Moreno et al., 2011).  Importantly, the inhibition 
of IMPDH is not only inhibitory to viral replication, but also affects cellular transcription 
10 
(Damonte and Coto, 2002).  
There is a need for a safer alternative to ribavirin.  One novel candidate is the base 
analog T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), also known as favipiravir.  
T-705 has been used to inhibit several positive- and negative-sense RNA viruses, but not 
DNA viruses (Clercq, 2012).  Like ribavirin, T-705 is converted in the cell to a 
nucleoside triphosphate, T-705RTP (figure 3B).   It has been shown to inhibit influenza 
replication by antagonizing the RdRp in a dose-dependent fashion and this effect could 
be reversed by the addition of GTP.  However, T-705RTP did not inhibit IMPDH (Furuta 
et al., 2005).  
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These results indicate T-705 may be a more specific inhibitor of viral replication 
with fewer off-target effects than ribavirin.   T-705 has been shown to effectively inhibit 
nonpathogenic arenaviral infection in tissue culture and rodent models (Gowen et al., 
2007).  However, T-705 has not been evaluated against highly pathogenic arenaviruses 
and its mechanism of action against arenaviruses remains undetermined.  In chapter 2, we 
determine the activity of T-705 against Junín, Machupo, and Guanarito viruses and we 
explore the mechanism of action of T-705 using the LCMV minigenome system..  
1d. The unique Arenaviral GPC and Inhibition of Fusion  
Entry is a promising step in the viral life-cycle for inhibiting the virus before it 
can usurp the host’s machinery and a better understanding of entry mechanisms will 
likely inform the search for antivirals (Rojek and Kunz, 2008).  Newly available small-
molecule inhibitors of membrane fusion may be the most promising new therapies to 
combat arenaviral infection (Bolken et al., 2006; Charrel and de Lamballerie, 2010; 
Larson et al., 2008).    Further, use of these fusion inhibitors may aid in probing the 
structure and function of GPC.  There are three main classes of viral fusion glycoproteins 
with varied organization, structures, and triggers.  However, they mediate a common 
function, membrane fusion, and they do so in a remarkably conserved manner.  In 
general, the fusion protein expressed on the viral envelope waits in a pre-fusion or a 
‘native’ state for an appropriate trigger.  This could be low pH and/or interaction with a 
host receptor.  Once triggered, the protein undergoes a series of conformational changes 
that result in the viral and cellular membranes fusing.  In class-I fusion, the fusion subunit 
extends and the receptor binding subunit is released, allowing the fusion peptide to be 
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inserted into the host membrane.   Now in a pre-hairpin intermediate form, this extended 
structure folds back on itself to form a trimer of hairpins.  This energetically favorable 
conformational change drives the merging of the two membranes (figure 5)  (Kim et al., 
2011; Schibli and Weissenhorn, 2004; White et al., 2008). 
 
 The arenaviral GPC is a class-I fusion protein (Gallaher et al., 2001).  Class-I 
fusion proteins exist as trimers in both the pre- and post- fusion state.  They are 
exemplified by their post-fusion adoption of a six-helix bundle.  This structure consists of 
a central N-terminal trimeric α-helical coiled-coil which is surrounded by 3 C-terminal 
helices (White et al., 2008).  Previous work in our laboratory has shown that the N- and 
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C- terminal heptad repeats in G2 (figure 6) are critical to fusion and can form a canonical 
six-helix bundle (York et al., 2005).   
GPC is synthesized as a single precursor protein that must be cleaved twice.  The 
first cleavage event is performed co-translationally by signal peptidase, which cleaves 
SSP.  The second proteolytic maturation step is performed by subtilisin kexin isozyme-
1/site-1-protease (SKI-1/S1P), which cleaves G1 and G2, and occurs in the Golgi 
apparatus.  Mature cleaved GPC is transported to the plasma membrane where virion 
budding occurs, mediated by Z (Emonet et al., 2009) (figure 2). Importantly, all three 
GPC subunits remain non-covalently associated with each other throughout the viral life 
cycle (figure 6).  This is unique to the arenaviral GPC.   
SSP is associated with G2 through its penultimate cysteine (C57), which 
participates in an intersubunit zinc binding domain (ZBD) (Briknarová et al., 2011; York 
and Nunberg, 2007a). As SSP remains associated with the mature glycoprotein complex, 
each trimeric GPC on the viral envelope contains nine TM domains.  Interestingly, SSP 
can be expressed in trans with a G1/G2 construct bearing the human CD4 signal peptide, 
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and these subunits will associate functionally to yield a mature GPC (York et al., 2004).  
Previous work has shown that SSP masks ER retention/retrieval signals in G2 and 
ergo, is essential to the proper trafficking, cleavage, and cell surface expression of GPC 
(Agnihothram et al., 2006).    SSP has also been shown to be essential for membrane 
fusion.  In Junín GPC (JGPC), lysine-33 (K33), in the short ectodomain loop of SSP, has 
been demonstrated to be critical in determining the pH at which fusion occurs.  
Substitution of K33 with the uncharged residue glutamine appears to stabilize the 
complex from pH-induced conformational change.  Compared to wild-type (wt) JGPC, 
which optimally fuses at pH5, K33Q requires a lower pH (4.5) to trigger membrane 
fusion.  Genetic studies have shown that compensating secondary mutations in the 
membrane-proximal region of G2 (D400A, E410A, R414A, K417A) are able to reverse 
the shift of pH-triggered fusion caused by the K33Q mutation (York and Nunberg, 2009).   
Together, the short ectodomain loop of SSP and the membrane-proximal region of G2 
form a pH-sensitive interface that is key to proper membrane fusion.   
Much study has been dedicated to this pH-sensitive, membrane-proximal interface 
between SSP and G2 and notably,  it is can be targeted by small-molecule inhibitors to 
prevent membrane fusion (York et al., 2008).  These inhibitors block pH-induced 
activation by stabilizing the pre-fusion form of GPC and they can be classified based on 
their specificity to OW viruses, NW viruses, or both.  Studies have shown that mutations 
within this membrane-proximal region can alter the sensitivity of GPC to these inhibitors.  
For example, mutations in the NW JGPC (T418N, L420T, A435I, I347A, D400A, K33H, 
K33R) reduce the sensitivity of JGPC to the NW specific fusion inhibitor ST-294.  
However, the mutation K33H confers sensitivity to the OW specific fusion inhibitor ST-
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161 (York et al., 2008). 
Interestingly, mutations within the transmembrane region of G2 have also been 
shown to be important to fusion (F427A, A435I, F438I, W428A) and drug sensitivity 
(F427A).  G2 mutations at residues F427, W428, and F438 also compensate for the 
K33Q fusion-deficient mutant.  (York and Nunberg, 2009; York et al., 2008).   
The TM regions within GPC are not uniformly hydrophobic.  Both the TM 
domain in G2 and the first TM region in SSP are predicted to form amphipathic helices 
while the second TM region of SSP has been shown to be resilient to alanine mutations 
and uniformly hydrophobic (Agnihothram et al., 2007).   My work in chapters 3-5 
focuses on furthering our understanding of the interactions between TM regions of SSP 
and G2.  
1e. Hypotheses and Significance 
 Without a licensed vaccine or treatment, arenaviruses continue to remain a 
significant threat to public health warranting further investigation into the biology of 
arenaviruses and treatment of arenaviral infections.  During my research I have focused 
on studying two aspects of arenavirus biology: the inhibition of viral replication by T-705 
and understanding the interactions between subunits within GPC. 
 T-705 is a promising new antiviral for the inhibition of RNA viruses and may be 
an alternative to the currently used ribavirin.  However, its ability to inhibit pathogenic 
arenaviral infections remained untested and it is important to learn more about its 
mechanism of action in arenaviral inhibition. In chapter 2, we hypothesized that T-705 
would specifically inhibit the viral RdRp with less cytotoxicity than ribavirin.  Consistent 
with this hypothesis, we demonstrated that three VHF viruses Junín, Machupo, and 
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Guanarito were inhibited by T-705 at similar concentrations to those used to inhibit the 
vaccine Candid-1 viral strain in tissue culture.  Importantly, time of addition studies 
demonstrated that T-705 is only effective during the middle of the viral life cycle, after 
entry and before budding, which is when viral replication occurs.  Using the LCMV MG 
system, I showed that T-705 inhibits viral polymerase activity at much lower 
concentrations than those required to interfere with cellular transcription, in contrast to 
ribavirin.  Using a panel of competing nucleosides and bases, I also demonstrated that T-
705 seems to be acting by a different mechanism than ribavirin.  These data are consistent 
with results others have observed using T-705 to inhibit influenza and serve as an 
important step in the development of T-705 as a treatment for acute arenaviral infection 
(Mendenhall et al., 2011).  
To further our goal of understanding the structure and function of GPC more 
precisely, we first sought in chapter 3 to identify the region(s) within SSP essential to 
fusion activity.  Because we know that the pH-sensitive, membrane-proximal interface is 
essential to membrane fusion, we hypothesized that the ectodomain loop of SSP would 
prove to be the most essential region.   However, we were surprised when our data 
indicated that a homotypic match between G2 and the first TM region of SSP was 
actually necessary and sufficient for fusogenicity.  Further, while it was previously 
accepted that the first TM region nominally began with E17 (Eichler et al, 2004), our 
studies suggest that this TM region actually begins at P12.  We discovered that residues 
P12 to K33 form a functional sub-domain within SSP and that sequence specificity 
within this domain is important to membrane fusion and drug sensitivity (Messina et al, 
2012).   
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This novel information prompted us to probe deeper into the potential interactions 
between SSP and G2.  Based on these new findings and previous data that indicate the 
TM region of G2 may be important to membrane fusion and drug sensitivity, we 
hypothesized that the first TM region of SSP interacts with the TM region of G2.  We 
explored two avenues to address this hypothesis.  I created a truncated GPC construct, 
termed TMCON, to serve as a potential model to study the  interactions between the G2 
TM and the first TM of SSP.  The generation and preliminary characterization of this 
construct is discussed in chapter 4. The other approach we used to pursue this hypothesis 
was to use cysteine-scanning mutagenesis and crosslinking experiments to study the 
orientation of the TM helices to each other within the trimeric GPC.  This approach and 
results are reviewed in chapter 5.  
The work I present here has furthered the understanding of T-705 in the treatment 
of arenaviral infection.  I developed a new biosafe fusion assay that does not rely on 
vaccinia virus as the current fusion assay used by the laboratory does (York et al., 2004).  
I used this novel assay to advance our understanding of how SSP interacts with G2 to 
mediate function.   I have also generated a  model construct for use in future studies for 
examining potential interactions between the first TM region of SSP and the TM region 
of G2.  Finally, I have attempted to map the arrangement of the transmembrane domains 
within GPC by creating a library of cysteine mutations and performing an exhaustive 
search for appropriate crosslinking conditions.  
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Chapter 2: T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell Culture 
Michelle Mendenhall, Andrew Russell, Terry Juelich, Emily L. Messina,
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This study was done in collaboration with Brian Gowen’s laboratory where the 
experiments using intact viruses were performed. I contributed the experiments involving 
the replicon system. 
 
Abstract 
 A number of New World arenaviruses (Junín [JUNV], Machupo [MACV], and 
Guanarito [GTOV] viruses) can cause human disease ranging from mild febrile illness to 
a severe and often fatal hemorrhagic fever syndrome. These highly pathogenic viruses 
and the Old World Lassa fever virus pose a significant threat to public health and national 
security. The only licensed antiviral agent with activity against these viruses, ribavirin, 
has had mixed success in treating severe arenaviral disease and is associated with 
significant toxicities. A novel pyrazine derivative currently in clinical trials for the 
treatment of influenza virus infections, T-705 (favipiravir), has demonstrated broad-
spectrum activity against a number of RNA viruses, including arenaviruses. T-705 has 
also been shown to be effective against Pichinde arenavirus infection in a hamster model. 
Here, we demonstrate the robust antiviral activity of T-705 against authentic highly 
pathogenic arenaviruses in cell culture. We show that T-705 disrupts an early or 
intermediate stage in viral replication, distinct from absorption or release, and that its 
antiviral activity in cell culture is reversed by the addition of purine bases and 
nucleosides, but not with pyrimidines. Specific inhibition of viral replication/transcription 
by T-705 was demonstrated using a lymphocytic choriomeningitis arenavirus replicon 
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system. Our findings indicate that T-705 acts to inhibit arenavirus 




Several New World arenaviruses, including Junín (JUNV), Machupo (MACV), 
and Guanarito (GTOV) viruses, as well as the related Old World Lassa virus, are among 
a phylogenetically diverse group of negative-sense RNA viruses that cause severe viral 
hemorrhagic fevers (VHFs) in regions of the world where they are endemic (Geisbert and 
Jahrling, 2004). The National Institutes of Health has classified these viruses as category 
A agents because of the threat they pose to the U.S. population (NAID, 2002). Despite 
the biodefense and public health risks associated with these highly pathogenic viruses, 
there are no FDA-licensed arenavirus vaccines and current antiarenaviral therapy is 
limited to an off-label use of ribavirin (1-β-d-ribofuranosyl-1,2,4-triazole-3-
carboxamide), which has had only mixed success in the treatment of severe infections 
and is associated with significant toxicity in humans (Enria et al., 2008; Khan et al., 
2008; Snell, 2001). Therefore, it is important to develop novel and effective antiviral 
drugs to combat arenaviral hemorrhagic fevers. 
T-705 (favipiravir; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is a pyrazine 
derivative with broad antiviral activity against RNA viruses, including influenza viruses 
(Furuta et al., 2002; Kiso et al., 2010; Sidwell et al., 2007; Sleeman et al., 2010), 
flaviviruses (Julander et al., 2009; Morrey et al., 2008), bunyaviruses, and several 
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nonpathogenic arenaviruses (Gowen et al., 2007, 2008, 2010). Moreover, studies 
employing the hamster Pichinde virus (PICV) infection model of acute arenaviral disease 
have demonstrated that T-705 can be used effectively to treat advanced infections in 
animals (Gowen et al., 2008). However, T-705 has not yet been tested against highly 
pathogenic human arenaviruses. 
Evidence indicates that T-705 is ribosylated and phosphorylated to the active T-
705-4-ribofuranosyl-5′-triphosphate form (T-705RTP) that inhibits influenza virus 
infection by interfering with viral RNA replication and transcription through inhibition of 
the virus RNA-dependent RNA polymerase (RdRp) (Furuta et al., 2005). The broad 
activity of T-705 against a number of RNA viruses suggests that this inhibitor may target 
a conserved functional element in the viral polymerase. The ability of T-705 to 
specifically target the viral replication machinery may minimize the possibility of in vivo 
toxicity. In contrast, ribavirin also inhibits cellular IMP dehydrogenase (IMPDH), a key 
enzyme in guanosine biosynthesis, and thereby perturbs cellular nucleotide pools. In the 
present study, we explored the mechanism of action of T-705 in cell culture and assessed 
the in vitro activity of T-705 against three highly pathogenic arenaviruses. 
B. Materials and Methods 
Viruses.  JUNV, Candid 1 strain (JUNV-C), and GTOV, strain S-26764, were provided 
by Robert Tesh at the World Reference Center for Emerging Viruses and Arboviruses 
(WRCEVA; University of Texas Medical Branch [UTMB], Galveston, TX). JUNV, 
Romero strain (JUNV-R), and MACV, strain Carvallo, were kindly provided by Tom 
Ksiazek (Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, 
21 
GA). Virus stocks of JUNV-R, MACV, and GTOV were grown in Vero (African green 
monkey kidney) cells. All work with JUNV-R, MACV, and GTOV was performed under 
biosafety level 4 (BSL4) containment at the Robert E. Shope Laboratory at UTMB. 
Tacaribe virus (TCRV), strain TRVL 11573 (ATCC, Manassas, VA), was 
passaged once in baby hamster kidney (BHK) cells and three times in Vero cells. The 
attenuated JUNV-C was passaged once in BSC-1 cells and once in Vero cells. Purified 
stocks were prepared for both TCRV and JUNV-C by sucrose cushion 
ultracentrifugation. Infected Vero cells culture lysates were clarified by low-speed 
centrifugation (4,500 × g), and the supernatants were overlaid onto a 20% (wt/vol) 
sucrose solution (TN buffer; 0.05 M Tris-HCl, pH 7.4, and 0.1 M NaCl) and centrifuged 
at 100,000 × g for 1 h in an SW28 rotor (Beckman Coulter, Brea, CA). The virus pellets 
were resuspended in phosphate-buffered saline (PBS), aliquoted, and stored at −80°C 
until use. 
Antiviral compounds, nucleotides, and nucleosides.  T-705 was provided by the 
Toyama Chemical Company, Ltd. (Toyama, Japan). Ribavirin was from MP Biomedical 
(Santa Ana, CA). Adenine, adenosine, guanine, guanosine, 2-deoxyguanosine, inosine, 
hypoxanthine, xanthine, cytosine, cytidine, thymine, thymidine, uracil, uridine, and uric 
acid were from Sigma (St. Louis, MO), and 2-deoxyadenosine, 2-deoxycytidine, and 
xanthosine were from ICN Nutritional Biochemicals (Cleveland, OH). 
 
Virus yield reduction assays.  For experiments evaluating drug inhibition of JUNV-R, 
MACV, or GTOV replication, Vero E6 (African green monkey kidney) cell cultures were 
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infected with a multiplicity of infection (MOI) of 0.1 in duplicates in the presence of 
serially 2-fold diluted (1,000 to 4 uM) T-705 or ribavirin. Supernatants from infected 
cells were harvested at 4 days postinfection (d p.i.) for MACV, 6 d p.i. for JUNV-R, or 
10 d p.i. for GTOV. 
Viral titers for drug-treated JUNV-R infections were determined by plaque assay. 
Vero E6 cells were infected with serial 10-fold dilutions of virus for 1 h at 37°C. Cell 
monolayers were then overlaid with 0.5% SeaKem ME agarose (Cambrex, East 
Rutherford, NJ) in minimal essential medium (MEM) supplemented with 2% fetal bovine 
serum (FBS) and 1% penicillin and streptomycin (P/S). Infected cells were cultured for 6 
days, at which time a second overlay containing 1% neutral red was added. PFU were 
counted 18 to 24 h after addition of the second overlay, and the 90% and 50% effective 
concentrations (EC90 and EC50, respectively) were calculated by regression analysis. 
GTOV titers were also measured by plaque assay. Vero cell monolayers were 
infected with serial 10-fold dilutions of GTOV for 1 h at 37°C. After infection, cells were 
overlaid with 0.5% methyl cellulose in MEM supplemented with 2% FBS and 1% P/S. 
After a 10-day culture period, the overlay was removed, and cells were fixed with 10% 
buffered formalin for 20 min and stained with 1% crystal violet (Sigma). PFU were 
counted, and the EC90 and EC50 were calculated by regression analysis. 
MACV titers were measured by a focus-forming unit (FFU) assay. Vero E6 
monolayers were infected with serial 10-fold dilutions of virus for 1 h at 37°C. Following 
infection, cells were overlaid with 0.8% tragacanth (Sigma) in MEM supplemented with 
2% FBS and 1% P/S. After infected cells were cultured for 4 days, the overlay was 
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removed, and cells were fixed with 10% buffered formalin for 30 min and then 
refrigerated overnight. Fixed cells were permeabilized in 70% ethanol for 20 min and 
washed with PBS. Primary antibodies were diluted in PBS with 5% milk and 1% Tween 
20. MACV-infected cells were incubated with primary antibody, JUNV-C antisera 
(kindly provided by R. Tesh, WRCEVA, UTMB), and incubated overnight at room 
temperature. The primary antibody was removed, and the plates were washed once with 
PBS. The secondary antibody, goat anti-mouse IgG labeled with horseradish peroxidase 
(HRP; Southern Biotech, Birmingham, AL), was diluted in PBS with 1% bovine growth 
serum and added to plates for 1 to 5 h at room temperature, and then the plates were 
washed with PBS. AEC substrate chromogen (DakoCytomation, Carpinteria, CA) was 
added for 15 min at room temperature. The reaction was stopped with distilled water, and 
fluid was removed from the wells. FFU were counted, and the EC90 and EC50 were 
calculated as described above. 
Time-of-addition and reversal of antiviral activity assays. In time-of-addition and 
reversal of antiviral activity assays, Vero monolayers (70% confluent) were first 
inoculated with TCRV or JUNV-C. Cells and virus were incubated at 37°C for 1 h to 
allow virus adsorption. The inoculum was removed, monolayers were washed twice, and 
test medium (MEM containing 2% FBS and 50 μg/ml gentamicin) was added to the 
wells. 
Two time-of-addition methods were employed. In method 1, monolayers were 
infected with TCRV or JUNV-C at an MOI of 0.2 (time zero), and T-705 was added at 1, 
2, 4, 6, 8, 10, 12, or 15 h p.i. to give a final concentration of 200 μM. Cells were 
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incubated at 37°C, and culture supernatants were collected at 24 h p.i. for virus yield 
determination by cell culture infectious dose assay (Gowen et al., 2007). Briefly, each 
sample was serially diluted in 10-fold increments and plated on Vero cells in 96-well 
microplates. Plates were incubated for 7 days, and viral cytopathic effect (CPE) was 
determined for calculation of 50% endpoints (50% cell culture infectious dose [CCID50]) 
as previously described (Reed and Muench, 1938). 
In the second method, cell monolayers in triplicate wells were infected with an 
MOI of 0.05, and cells were treated by adding T-705 to a final concentration of 400 μM 
for the indicated periods (−2 to 0, 0 to 3, 3 to 6, 6 to 9, 9 to 12, 12 to 15, and 15 to 18 h 
p.i.). Test medium was replaced, and incubation was continued. Cells were incubated at 
37°C, supernatants were collected 24 h p.i., and virus yields were determined. 
Reversal of antiarenaviral T-705 activity by the addition of a molar excess of 
purine and pyrimidine bases and nucleosides was investigated with Vero cells infected 
with an MOI of 0.2 of TCRV or JUNV-C. T-705 was added to a final concentration of 
200 μM; each competitive agent was added to triplicate wells to a final concentration of 
400 μM. Cells were incubated at 37°C until 48 h p.i., at which time supernatants were 
collected and virus yields determined. 
LCMV MG rescue assay.  The lymphocytic choriomeningitis arenavirus (LCMV) 
minigenome (MG) rescue assay was used as previously described (Lee et al., 2000, 
2002). Briefly, BHK-21 cells were transfected with one plasmid that directs synthesis of 
an LCMV MG RNA expressing the firefly luciferase (fLuc) reporter gene in an antisense 
orientation together with two polymerase II expression plasmids encoding the L 
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polymerase (pC-L) and nucleoprotein (pC-NP), required for MG replication and 
expression. The plasmid mixture was transfected at a 1:2:1 ratio of MG-fLuc-pC-L-pC-
NP using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). To assess potential cytotoxic 
effects of T-705 and ribavirin, the cells were also cotransfected with the pRL-CMV 
plasmid (Promega, Madison, WI) expressing the Renilla luciferase (RLuc) reporter gene 
under the control of cellular, rather than viral, transcription machinery. Four hours later, 
cells were reseeded into 96-well microculture dishes and incubated for 44 h with replicate 
serial dilutions of T-705 or ribavirin. Cells were then lysed, and fLuc and RLuc activities 
were detected using a dual reporter assay kit (Promega) and SpectraMax L luminometer 
(Molecular Devices, Sunnyvale, CA). 
Reversal of T-705 and ribavirin activity in the LCMV replicon system by the 
addition of purine or pyrimidine bases and nucleosides was also investigated with BHK 
cells using the LCMV replicon system. T-705 or ribavirin was added to cells at a final 
concentration of 200 or 100 μM, respectively, and each base/nucleoside was added to a 
final concentration of 400 μM. Cells were lysed 48 h posttransfection and assayed for 
bioluminescence. 
C. Results 
T-705 activity against hemorrhagic fever-causing arenaviruses.  T-705 has been 
shown to inhibit the replication of several nonpathogenic arenaviruses but has not to date 
been tested for activity against the highly pathogenic viruses known to cause VHFs. 
Therefore, we evaluated the inhibitory activity of T-705 in JUNV-R, MACV, and GTOV 
infection. As shown in Table 1, T-705 was effective against GTOV, JUNV-R, and 
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MACV at inhibitory concentrations similar to those reported for JUNV-C and other 
nonpathogenic arenaviruses (Gowen et al., 2007). Ribavirin was also effective against the 
three viruses, but to a lesser degree, as reflected by higher inhibitory concentrations 
(Table 1) and right-shifted dose-response curves (figure 7) relative to T-705. Evidence of 
cytotoxicity by either compound was not observed at the tested concentrations. 
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T-705 time-of-addition effect on arenavirus multiplication in cultured cells. Time-of-
addition studies were conducted to assess the stage of arenaviral replication at which T-
705 imparts its antiviral activity. Inhibitor was added at various times p.i., and the 
reduction in virus production relative to the untreated culture was assessed at 24 h p.i. In 
untreated cultures, infectious TCRV and JUNV-C particles could be detected in the 
supernatant by 14 h (not shown), suggesting an eclipse period of approximately 14 h. 
TCRV replication was inhibited when drug was added up to 6 h p.i. and left on 
throughout the 24-h incubation period (figure 8, left). With JUNV-C, inhibition was seen 
when T-705 was withheld until as late as 8 h p.i. (figure 8, right). Robust inhibition was 
28 
observed generally in cultures treated within 6 to 8 h of infection. As T-705 is likely 
metabolized by the cell to form T-705RTP (Smee et al., 2009), these times represent 
minimal estimates for T-705 sensitivity. Nonetheless, the data suggest that T-705 acts at 
early or middle stages of the virus life cycle. 
 To investigate the timing of inhibition by T-705 in more detail, we conducted 
experiments wherein cells were exposed to the drug for short periods within the 24-h time 
frame of the experiment. The most robust inhibition of TCRV and JUNV-C replication 
was observed upon T-705 treatment during postinfection periods of 3 to 6 h, 6 to 9 h, 9 to 
12 h, and 12 to 15 h (figure 8B). Little or no inhibition was seen when T-705 was added 
from −2 to 0 h, 0 to 3 h, or 15 to 18 h p.i. Taken together, these studies suggest a window 
for T-705 inhibition within the early and intermediate stages of virus replication, 
following virus entry and prior to virus assembly and budding. 
Effects of purines at molar excess concentration on T-705-mediated anti-TCRV and 
-JUNV-C activity.  Based on a previous study demonstrating that the antiviral action of 
T-705 in influenza virus-infected cells could be reversed by the addition of purines or 
purine nucleosides, but not by pyrimidines (Furuta et al., 2005), we investigated the 
requirements for the reversal of T-705 activity in arenavirus infection. As seen in figure 
9, TCRV and JUNV-C production could be rescued from T-705 action by the addition of 
a molar excess of purines, including adenine, adenosine, 2-deoxyadenosine, guanine, 
guanosine, 2-deoxyguanosine, inosine, and hypoxanthine. In contrast, compounds 
generated in purine catabolism (xanthine and uric acid) and xanthosine did not reverse 
the action of T-705. Likewise, the pyrimidine nucleobases (cytosine, thymine, and uracil) 
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and nucleosides (cytidine, 2-deoxycytidine, thymidine, and uridine) had little or no 
impact on T-705 anti-arenavirus activity. 
 
Effect of T-705 on the activity of an LCMV MG. Previous studies have shown that 
arenavirus replication can be modeled using a recombinant plasmid replicon system 
comprising the viral RdRp (L), the nucleoprotein (N), and an RNA MG (Flatz et al., 
2006; Lee et al., 2000, 2002; Rusnak et al., 2009). To specifically investigate the effects 
of T-705 on viral replication and transcription, we made use of the LCMV replicon 
system. In this assay, RdRp-dependent replication of the antigenomic viral RNA is 
evidenced by expression of a firefly luciferase (fLuc) reporter gene in the MG RNA. 
Inhibition of fLuc expression in cells transfected with the three-plasmid replicon would 
be consistent with a disruption of RdRp function. As shown in figure 10A, transcription 
from the LCMV replicon system was inhibited by T-705 (EC50 of 29 μM). Cell-driven 
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expression of a cotransfected Renilla luciferase (RLuc) plasmid, which provides a 
measure of the effects on cellular transcription, was minimally affected at the highest 
concentrations of T-705 tested (figure 10B). This result demonstrates the specificity and 
apparent absence of general cytotoxicity by T-705. Ribavirin was also shown to inhibit 
fLuc expression by the LCMV replicon (EC50 of 13 μM), but considerable cytotoxicity 
(50% cytotoxic concentration [CC50] of ∼100 μM) was also observed (figure 10B). This 
cytotoxic effect likely contributes to the unusually steep dose-response curve observed 
for ribavirin (figure 10A) and artifactually reduces its EC50. 
Consistent with our antiviral studies, the inhibitory action of T-705 was also reversed by 
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purines and purine nucleosides when assessed using the LCMV replicon system. 
Significant rescue from inhibition was provided by adenine, adenosine, 2-
deoxyadenosine, 2-deoxyguanosine, inosine, and hypoxanthine (figure 11). Guanine and 
guanosine also reversed the effect of T-705, albeit to a lesser extent. The pyrimidines, as 
well as xanthine, xanthosine, and uric acid, were again inactive in this assay. Inhibition 
by ribavirin was also partly reversed by guanine and guanosine. In contrast to T-705, 
however, the addition of adenine or adenosine did not prevent inhibition by ribavirin. 
This is consistent with the known inhibitory effect of ribavirin on the cellular IMPDH, 
which is not involved in adenosine biosynthesis. This observation suggests that the target 
for inhibition by T-705 is distinct from that of ribavirin, which appears to act 









T-705 has demonstrated remarkably broad in vitro activity against a range of 
RNA viruses.  For many of these viruses, treatment options are severely limited, and in 
the case of influenza virus, oseltamivir resistance remains a concern (Bloom et al., 2010). 
In particular, therapeutic options for treating severe arenaviral hemorrhagic fever cases 
are restricted to the use of ribavirin (Borio et al., 2002) or, in the case of Argentine 
hemorrhagic fever, to transfusion of immune plasma. Safer and more effective 
countermeasures are clearly needed (Enria et al., 2008; Khan et al., 2008). T-705 is 
currently being evaluated in clinical trials in Japan and the United States for use in the 
treatment of influenza virus infections (Furuta et al., 2009). FDA approval for the safe 
use of T-705 for influenza virus infection would facilitate its development for other RNA 
virus treatment indications. Here, we have demonstrated for the first time that T-705 is 
active against the highly pathogenic human arenaviruses JUNV-R, MACV, and GTOV 
and provided evidence that suggests that T-705 may act as a purine nucleoside analog 
specifically targeting arenaviral RdRp. 
A recent study exploring the mechanism of action of T-705 against influenza 
virus infection suggests that the viral polymerase is the principal target of the active T-
705 metabolite T-705RTP (Furuta et al., 2005). We hypothesize that T-705 is also able to 
inhibit arenavirus multiplication by targeting the virus polymerase complex. It has been 
shown that influenza virus replication is inhibited by T-705 at an early or middle stage of 
infection and that purines but not pyrimidines are able to competitively reverse anti-
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influenza virus activity (Furuta et al., 2005).  In the present study, we observed analogous 
results in arenavirus infection. 
In our studies of the reversal of T-705 inhibition, nearly all purine-based 
compounds showed a significant effect on T-705 activity. The notable exceptions were 
uric acid, xanthine, and xanthosine. Uric acid is the end product of purine degradation 
and would thus not be expected to affect inhibition by T-705. The biological 
consequences of xanthine and xanthosine metabolism are poorly defined. Indeed, all 
biosynthetic and catabolic purine pathways in the cell are highly interconnected and 
tightly regulated, making it difficult to ascribe a specific mechanism for the reversal of T-
705 inhibition. However, in in vitro assays of influenza virus RdRp activity, GTP has 
been shown to be competitive with T-705RTP (Furuta et al., 2005).  Further biochemical 
studies are needed to test the leading hypothesis that T-705 acts as a nucleoside analog to 
inhibit the arenaviral RdRp. Additional information from the analysis of T-705 resistance 
will also be helpful in identifying the precise viral target. 
Inhibition of the LCMV MG system indicates that T-705 interferes with virus 
transcription and/or replication. The molecular mechanism for inhibition, however, is not 
known and may include effects on L, NP, or MG. Cellular transcription, as measured by 
the RLuc reporter, was unaffected. In contrast, ribavirin demonstrated significant 
inhibition of cellular processes at concentrations only slightly greater than those that 
inhibit the LCMV replicon. This is consistent with its known inhibition of IMPDH 
(Furuta et al., 2005; Streeter et al., 1973) and its recognized in vivo toxicity(Chapman et 
al., 1999; Rusnak et al., 2009). The ability of hypoxanthine to reverse inhibition by T-
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705, but not by ribavirin, provides additional evidence that T-705 does not inhibit cellular 
IMPDH (Weber et al., 1992). The specific inhibitory activity of T-705 against South 
American VHF viruses and its apparent lack of cellular toxicity bode well for further 
development of T-705 in the treatment of severe arenaviral hemorrhagic fevers. 
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Abstract 
The arenavirus envelope glycoprotein (GPC) retains a stable signal peptide (SSP) as an 
essential subunit in the mature complex. The 58-amino-acid residue SSP comprises two 
membrane-spanning hydrophobic regions separated by a short ectodomain loop that 
interacts with the G2 fusion subunit to promote pH-dependent membrane fusion. Small-
molecule compounds that target this unique SSP-G2 interaction prevent arenavirus entry 
and infection. The interaction between SSP and G2 is sensitive to the phylogenetic 
distance between New World (Junín) and Old World (Lassa) arenaviruses. For example, 
heterotypic GPC complexes are unable to support virion entry. In this report, we 
demonstrate that the hybrid GPC complexes are properly assembled, proteolytically 
cleaved, and transported to the cell surface but are specifically defective in their 
membrane fusion activity. Chimeric SSP constructs reveal that this incompatibility is 
localized to the first transmembrane segment of SSP (TM1). Genetic changes in TM1 
also affect sensitivity to small-molecule fusion inhibitors, generating resistance in some 
cases and inhibitor dependence in others. Our studies suggest that interactions of SSP 
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TM1 with the transmembrane domain of G2 may be important for GPC-mediated 
membrane fusion and its inhibition.  
A. Introduction 
Arenaviruses comprise a diverse family of enveloped negative-strand RNA 
viruses that are endemic to rodent populations worldwide. Infection can be transmitted to 
humans to cause severe acute hemorrhagic fevers with high morbidity and mortality. 
Lassa fever virus (LASV) is prevalent in western Africa, infecting a half-million persons 
annually (McCormick et al., 1987). Five species of New World (NW) hemorrhagic fever 
viruses are distributed throughout South America, including the Junín virus (JUNV) in 
Argentina. New arenavirus species frequently emerge from rodent reservoirs (Briese et 
al., 2009; Centers for Disease Control and Prevention (CDC), 2000; Eichler et al., 2003). 
In the absence of effective vaccines or therapies, the hemorrhagic fever arenaviruses are 
recognized to pose significant threats to public health and biodefense. Accordingly, these 
viruses are classified as Category A priority pathogens, and JUNV has additionally been 
determined by the Department of Homeland Security to pose a Material Threat to the 
U.S. population.  
Arenavirus entry into the host cell is mediated by the virus envelope glycoprotein 
(GPC) (figure 12). Upon binding to a cell surface receptor (reviewed in references (Choe 
et al., 2011; Rojek and Kunz, 2008), the virion is endocytosed, and GPC-mediated fusion 
of the viral and endosomal membranes is activated upon acidification in the maturing 
endosome. GPC is synthesized as a precursor glycoprotein and cleaved by the cellular 
SKI-1/S1P protease in the Golgi (Kunz et al., 2003; Lenz et al., 2001) to generate the 
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receptor-binding (G1) and transmembrane fusion (G2) subunits. The mature GPC 
complex is metastable and thus primed to mediate membrane fusion in response to acidic 
pH. Upon activation, GPC undergoes a series of conformational changes leading to 
formation of a trimer-of-hairpins structure (Eschli et al., 2006; Igonet et al., 2011; York et 
al., 2010) and fusion of the viral and cellular membranes (reviewed in 
references(Harrison, 2008; White et al., 2008)). The arenavirus GPC is unique among 
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class I envelope glycoproteins in that it retains its cleaved signal peptide as a third 
subunit (Eichler et al., 2003; Froeschke et al., 2003; York et al., 2004).  
The 58-amino-acid stable signal peptide (SSP) of GPC contains two hydrophobic 
segments that span the membrane and are joined by a short ectodomain loop figure 12 
(Agnihothram et al., 2007). The cytoplasmic N terminus of SSP is myristoylated, while 
the penultimate C-terminal cysteine (C57) coordinates with a zinc-binding domain in the 
cytoplasmic tail of G2 to form an intersubunit structure that anchors SSP in the GPC 
complex (Briknarová et al., 2011; York and Nunberg, 2007a).  SSP association masks 
endogenous endoplasmic reticulum (ER) retention/retrieval signals in the cytoplasmic 
domain of G2 to facilitate GPC transport through the Golgi (Agnihothram et al., 2006), 
whereupon the precursor is proteolytically cleaved and transported to the cell surface for 
virion assembly.  
Our studies suggest that pH-induced activation of the mature GPC complex is 
controlled by a unique interaction between the short ectodomain loop of SSP and the G2 
fusion subunit. Side chain substitutions that reduce positive polarity at SSP K33 depress 
the pH required to trigger membrane fusion (York and Nunberg, 2006) , and this 
phenotype can be rescued by secondary mutations in G2 (York and Nunberg, 2009). 
Importantly, this SSP-G2 interaction provides a molecular target for small-molecule 
compounds that stabilize the prefusion GPC complex, thereby preventing pH-induced 
activation in the endosome (Bolken et al., 2006; Larson et al., 2008; Lee et al., 2008; 
York et al., 2008).  The different classes of fusion inhibitors demonstrate distinct patterns 
of specificity against New World (NW) and Old World (OW) arenaviruses yet share a 
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binding site on GPC (Bolken et al., 2006; Larson et al., 2008; Thomas et al., 2011; York 
et al., 2008).  Sequence variation at the nominal SSP-G2 interface likely accounts for the 
differences in species specificity ( Thomas et al., 2011; York et al., 2008). Several of 
these fusion inhibitors have recently been shown to protect against lethal arenavirus 
disease in animal models (Bolken et al., 2006; Cashman et al., 2011).  
Sequence variation between OW and NW arenavirus species may also affect the 
ability of one SSP to function in the context of a heterotypic GPC complex. For instance, 
recombinant JUNV virions in which SSP and the G1G2 precursor are heterotypic are not 
viable (Albariño et al., 2011). We have exploited this interspecies incompatibility 
between LASV and JUNV GPCs to identify determinants in SSP required for membrane 
fusion activity. We found that SSP association, proteolytic maturation, and transport to 
the cell surface are promiscuous in interspecific hybrid GPCs and that heterotypic SSPs 
support these functions in the context of either JUNV or LASV G1G2 precursors. 
Preservation of pH-dependent membrane fusion, however, requires a specific homotypic 
match in the first transmembrane domain (TM1) of SSP. We propose that this 
amphipathic helical region of SSP interacts with the transmembrane domain of G2 and 
thus contributes to the pH-dependent membrane fusion activity of arenavirus GPC.  
B. Materials and Methods 
Plasmids. GPC from the pathogenic MC2 isolate of JUNV (Ghiringhelli et al., 1991) and 
from the Josiah isolate of LASV (Larson et al., 2008) was expressed using the minimal 
T7 promoter sequence in pcDNA 3.1-based vectors (Life Technologies). In order to 
obviate concerns regarding signal peptidase cleavage of SSP in the chimeric GPC 
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constructs, SSP and G1G2 open reading frames were expressed from separate plasmids, 
taking advantage of the ability of the two polypeptides to associate in trans to reconstitute 
the functional GPC complex (Eichler et al., 2003; York and Nunberg, 2007b).  The G1G2 
precursor was directed to the membrane using the conventional signal peptide of human 
CD4, as previously described (York and Nunberg, 2007b). An innocuous FLAG affinity 
tag was appended to the C terminus of LASV G1G2 to facilitate detection (York et al., 
2004). SSP chimeras were constructed using conventional PCR procedures, and 
mutations were introduced using QuikChange methodology (Stratagene).  
Antibodies and small-molecule entry inhibitors .JUNV G1-specific monoclonal 
antibodies (MABs) BF11 and BE08 (Sanchez et al., 1989) were obtained through the 
NIAID Biodefense and Emerging Infections Research Resources Program 
(BEIResources) and the FLAG peptide-specific MAB (M2) was purchased from Sigma. 
The LASV G1-specific MAB L52 134-23 (Ruo et al., 1991) was kindly provided by 
Connie Schmaljohn (USAMRIID). The small-molecule fusion inhibitors ST-294, ST-
193, ST-161, and ST-761 have been previously described (Bolken et al., 2006; Larson et 
al., 2008; Thomas et al., 2011; York et al., 2008) and were kindly provided by SIGA 
Technologies (Corvallis, OR).  
Analysis of GPC expression. GPC was expressed by transient transfection in Vero cells 
infected with the vTF-7 vaccinia virus expressing T7 polymerase (Fuerst et al., 1986) or 
in engineered BHK-21 cells expressing T7 polymerase (BSR T7/5) (Buchholz et al., 
1999), kindly provided by Klaus Conzelmann (Ludwig-Maximilians-University Munich). 
Proteins were metabolically labeled using 
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S-labeled amino acids (Perkin Elmer) and 
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immunoprecipitated with the appropriate MAB as previously described  (York and 
Nunberg, 2007b).   Flow cytometric detection of cell surface GPC was hindered by low 
levels of expression using our pcDNA-based vectors in BSR T7/5 cells, especially for 
LASV GPC (see Results and Discussion). Therefore, for these studies GPC was 
expressed in Vero cells using a pCAGGS-MCS vector (Niwa et al., 1991) provided by 
Juan Carlos de la Torre (Scripps Research Institute) (Urata et al., 2011). Cell surface 
expression was determined using the JUNV G1-specific MAB BE08 (Sanchez et al., 
1989)or the LASV G1-specific MAB L52 134-23 (Ruo et al., 1991), and a secondary 
fluorescein isothiocyanate (FITC)-labeled anti-mouse immunoglobulin antibody. The cell 
populations were stained with propidium iodine to exclude dead cells, fixed with 2% 
formaldehyde, and analyzed using a FACSCalibur flow cytometer (BD Biosciences).  
Analysis of GPC-dependent membrane fusion .The recombinant vaccinia virus-based 
assay for GPC-mediated cell-cell fusion was performed as previously described  (York 
and Nunberg, 2006). Briefly, Vero cells infected by vTF-7 and expressing GPC are 
cocultured with cells infected with a recombinant vaccinia virus vCB21R-lacZ bearing 
the β-galactosidase gene under the control of the T7 promoter (Nussbaum et al., 1994). 
Cell-cell fusion is triggered by exposure to medium adjusted to pH 5.0 and detected 
through β-galactosidase expression in the newly formed syncytia. Fusion is quantitated 
by chemiluminescence using the GalactoLite Plus substrate (Life Technologies). Fusion 
inhibition by small-molecule SIGA compounds was determined as previously described 
(York et al., 2008) and GraphPad Prism software was used for nonlinear regression 
calculations using a single-slope dose-response model constrained to 100% fusion in the 
absence of inhibitor.  
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In order to circumvent biosafety concerns associated with the use of vaccinia 
viruses, we developed an alternative fusion reporter assay based on expression of T7 
polymerase in BSR T7/5 cells. In this format, GPC-expressing BSR T7/5 cells were 
cocultured with human 293T cells transfected with the internal ribosome entry site 
(IRES)-containing pT7EMC-luc reporter plasmid expressing luciferase under the control 
of the T7 promoter (Satoh et al., 2008), which was kindly provided by Yoshiharu 
Matsuura (Osaka University). Following a 5-min exposure to medium adjusted to pH 5.0, 
the coculture was continued at neutral pH for 12 h to allow for luciferase expression. 
Cell-cell fusion was detected using the luciferase assay kit substrate (Promega). 
Consistency of GPC expression was monitored by immunohistochemical staining. 
Results from this novel fusion reporter assay were validated in parallel experiments using 
the well-established vaccinia virus-based assay.  
C. Results and Discussion 
Divergence between JUNV and LASV SSPs.  A comparison of the amino acid 
sequences of JUNV and LASV SSPs reveals a high degree of sequence divergence, as 
well as an overall conservation of sequence motifs (figure 12). The two hydrophobic 
domains (hϕ1 and hϕ2) in each are separated by a short region containing the conserved 
K33 residue (York and Nunberg, 2006). A myristoylation motif and zinc-coordinating 
cysteine (C57) are present in both N- and C-terminal cytoplasmic domains, respectively 
(Agnihothram et al., 2007). Both SSPs are also predicted to possess similar secondary 
structure features, with two helical regions interspersed by an unstructured ectodomain 
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Hybrid GPC containing heterologous SSP and G1G2.  Reverse-genetics studies have 
shown that hybrid GPC complexes are functional for arenavirus infection if and only if 
SSP is homotypic with the TM and C-terminal cytoplasmic domains of G2 (Albariño et 
al., 2011). To investigate the molecular basis for this finding, we characterized the 
assembly, transport, and function of hybrid GPCs. Taking advantage of the observation 
that SSP can associate in trans with the G1G2 precursor to reconstitute the functional 
GPC complex (Eichler et al., 2003; York et al., 2004), we coexpressed JUNV or LASV 
SSP with the reciprocal G1G2 precursors, which contained the conventional signal 
peptide of human CD4 (York and Nunberg, 2007b; York et al., 2004). Membrane fusion 
activity of the homologous and heterologous hybrid GPCs was determined using a 
biosafe modification of the well-characterized vaccinia virus-based cell-cell fusion assay 
(York et al., 2004). BSR T7/5 cells expressing the bacteriophage T7 polymerase 
(Buchholz et al., 1999) were cotransfected with pcDNA3.1-based plasmids expressing 
SSP and the G1G2 precursor under the control of the T7 promoter. These cells were then 
cocultured with 293T fusion reporter cells expressing luciferase in a T7 polymerase-
dependent manner. Cell-cell fusion was initiated by exposing the coculture to medium 
adjusted to pH 5.0, and luciferase expression in the newly formed syncytia was 
determined following continued incubation at neutral pH. Using this assay, we verified 
that neither of the two heterotypic GPC hybrids (JUNV SSP with LASV G1G2 or LASV 
SSP with JUNV G1G2) was able to mediate membrane fusion (figure 13A). Concordant 
cell-cell fusion results were obtained using the vaccinia virus-based fusion reporter assay 
((York et al., 2004) and data not shown).  
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Hybrid GPC assembles and is transported to the cell surface. To determine the 
molecular basis of heterotypic incompatibility, we first investigated the ability of SSP to 
associate with the G1G2 precursor. It is possible that the absence of membrane fusion 
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activity reflects an inability of SSP to bind the heterologous G1G2 precursor, thereby 
preventing GPC transport through the Golgi, proteolytic maturation, and cell surface 
expression. To assess GPC biogenesis, SSP and the G1G2 precursor were expressed in 
trans, and metabolically labeled GPC was immunoprecipitated (York and Nunberg, 
2007b) using MABs directed to either JUNV G1 (Sanchez et al., 1989) or the C-terminal 
FLAG tag on LASV G2. We found that GPC protein synthesis was markedly reduced in 
BSR T7/5 cells relative to that typically seen in Vero cells infected with recombinant 
vaccinia viruses expressing T7 polymerase (Fuerst et al., 1986; York et al., 2004), 
presumably reflecting the absence of mRNA capping in the cytosol of transfected BSR 
T7/5 cells. Nevertheless, SDS-PAGE analysis showed that SSP association in the 
heterotypic GPCs was similar to that in the homotypic complex (figure 14A). 
Furthermore, this association was sufficient to promote a significant degree of proteolytic 
maturation of the heterologous G1G2 precursor (figure 14A).   Flow cytometry was used 
to confirm trafficking of the heterotypic GPC hybrids to the cell surface. Due to the low 
level of expression of LASV GPC in BSR T7/5 cells (figure 14A), we used a well-
characterized pCAGGS plasmid vector (Niwa et al., 1991)  for these studies of GPC 
transport(Urata et al., 2011). Cell surface accumulation of heterologous GPC hybrid was 
found to be similar to that of the homotypic protein in both cases (figure 14B).  As GPC 
transport does not require proteolytic cleavage (Agnihothram et al., 2006; Schibli and 
Weissenhorn, 2004), these findings assess an independent function of SSP association. 
Conversely, transit of GPC through the Golgi, as evidenced by proteolytic cleavage, is 
predictive of cell surface expression. Despite substantial sequence divergence, both 
heterologous SSPs were capable of promoting the assembly and maturation of the hybrid 
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GPC complex, as well as its transport to the plasma membrane. This result agrees with 
previous studies using a recombinant LASV GPC encoding JUNV SSP (Albariño et al., 
2011). Because very low levels of mature GPC are sufficient to support membrane fusion 
activity (Agnihothram et al., 2007; York et al., 2005), we surmise that the partial 
reductions in SSP association and proteolytic cleavage in the heterotypic GPC hybrids are 
by themselves insufficient to explain the complete loss of fusogenicity. This conclusion is 
reinforced by the overall lack of correlation between variations in proteolytic cleavage 
and membrane fusion activity in studies using chimeric SSP molecules (see below).  
Interchange of the ectodomain loop in SSP.  We have previously shown that the short 
ectodomain loop of SSP is critical for pH-dependent membrane fusion and its inhibition 
by small-molecule inhibitors (York and Nunberg, 2006; York et al., 2008). This region of 
JUNV SSP is defined by charged residues at the ectodomain termini of TM1 and TM2 
(K33 and K40, respectively) (figure 12). We therefore subdivided SSP into three regions 
for purposes of constructing chimeras: region 1 included the myristoylated N terminus of 
SSP and TM1 (residues M1 to K33), region 2 comprised the ectodomain loop (K33 to 
K40 in JUNV, T40 in LASV), and region 3 contained TM2 and the short cytoplasmic 
domain bearing C57 (to the C-terminal T58). All combinations of the three JUNV and 
LASV subdomains were constructed (figure 13A), and the chimeric SSPs were named 
according to the three regions. For instance, JJJ represents the wild-type JUNV SSP and 
JLJ signifies a chimera in which the ectodomain from LASV was fused to regions 1 and 3 
of JUNV SSP. For clarity, we will refer to recombinant SSPs as chimeras and reserve the 
term hybrid for the reconstituted GPC complex.  
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As anticipated from the fully heterotypic GPC hybrids (figure 14A) , all of the 
chimeric SSPs associated with the JUNV G1G2 precursor and supported proteolytic 
cleavage in BSR T7/5 cells (figure 15). Parallel metabolic labeling studies using LASV 
GPC again showed poor expression but nonetheless allowed similar conclusions (not 
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shown). These findings were further validated using recombinant vaccinia virus to drive 
GPC expression ((York et al., 2004) and data not shown). We conclude that the sequence 
requirements for SSP association and proteolytic maturation are relatively relaxed in 
interspecific GPC chimeras.  
Despite its critical role in membrane fusion, interspecific exchange of the 
ectodomain loop had little effect on the fusion activity of hybrid GPCs (figure 13). LJL 
did not restore fusion activity to the JUNV G1G2 hybrid (∼3% of wild-type JUNV GPC) 
and likewise the reciprocal JLJ SSP in the LASV G1G2 hybrid (<1% of wild-type LASV 
GPC). Conversely, replacement of the ectodomain in JUNV SSP with that of LASV (JLJ) 
had a relatively small effect on the fusion activity of the hybrid JUNV GPC (∼40% of 
JUNV GPC). The reciprocal hybrid, LASV G1G2 bearing LJL SSP, retained a lower 
albeit significant level of activity (∼10% of LASV GPC). We conclude that a homotypic 
ectodomain loop in SSP is neither sufficient nor absolutely necessary to support 
membrane fusion by the hybrid GPC complex.  
Region 1 of SSP is essential for membrane fusion activity.  Analysis of the remaining 
SSP chimeras did reveal an important role for the N-terminal region 1 in SSP function. 
Only LASV hybrids containing the homologous region 1 (LJL, LLJ, and LJJ) showed 
significant membrane fusion activity (figure 13A). Whereas the LJL hybrid supported 
∼10% of wild-type activity (above), the latter two SSP chimeras promoted cell-cell 
fusion at levels comparable to those of native LASV GPC. The reciprocal pattern was 
seen with the JUNV G1G2 precursor and the JLJ, JJL, and JLL chimeras. In JUNV GPC, 
SSP bearing a mismatch in regions 1 and 2 (LLJ) unexpectedly also exhibited fusion 
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activity (∼20% of the wild type). By comparison, all hybrids displayed similar patterns of 
GPC expression (figure 15). Taken together, these results indicate that homotypic pairing 
in SSP region 1 is paramount for membrane fusion activity. Region 2 appears to 
contribute somewhat to activity when the homologous region 1 is present (JJL and LLJ), 
whereas homology in region 3 is relatively unimportant. The reciprocal relationship 
between JUNV and LASV hybrids validates the importance of region 1 as a determinant 
of GPC-mediated membrane fusion.  
The apparent indifference to sequence variation in region 3 is consistent with 
previous results from mutational studies (Agnihothram et al., 2007). Triplet alanine 
replacements in TM2 of JUNV SSP (44FQF46 and 47FVF49 mutants) have no effect on 
fusogenicity. Similarly in the short C-terminal cytoplasmic tail of SSP, only the 
conserved C57 side chain is essential for membrane fusion activity (York and Nunberg, 
2007b). Collectively, these observations suggest a lack of sequence specificity in the 
function of region 3. However, the presumed helical nature of TM2 appears to be 
important, as SSP association is completely abrogated by single amino acid deletions that 
are expected to alter the register of the helix (Agnihothram et al., 2007).  
TM1 forms an extended helical domain.  To further dissect the role of region 1 in 
fusogenicity, we bisected the N-terminal cytoplasmic and TM regions using the 
conserved E17 as the nominal cytosolic junction of TM1. Thus, the (J1L2) exchange in 
region 1 comprised JUNV residues M1 to E17 and LASV residues E17 to K33 (figure 
13B).  SSPs including the reciprocally exchanged sequences (J1L2 and L1J2) associated 
with and supported proteolytic maturation of both JUNV (figure 15) and LASV 
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precursors (not shown) but were entirely defective in promoting membrane fusion (figure 
13B).  In contrast, the parental SSP chimeras containing the intact region 1 (JJL and LJL) 
produced functional hybrids with their respective G1G2 precursors. The symmetric loss 
of fusogenicity at this junction is likely to reflect an internal sequence incompatibility 
within the SSP chimeras rather than between SSP and G2.  
Secondary structure predictions suggested a possible explanation for this 
intramolecular incompatibility (figure 12). For both JUNV and LASV SSP, prediction 
algorithms (Rost and Sander, 1993) suggest that the helical structure of TM1 extends N 
terminally to the conserved proline at position 12. To test this notion, we generated 
additional region 1 exchanges in which TM1 was extended N terminally to P12. We 
found that an SSP chimera including the extreme N-terminal residues of LASV (residues 
M1 to P12) and the extended helical region of JUNV (residues P12 to K33), referred to as 
(LexJ)JL, supported cell-cell fusion comparably to the parental JJL chimera in the hybrid 
JUNV GPC (figure 13B).  Likewise, SSPs containing the (JexL)LJ and (JexL)JL 
exchanges promoted detectable fusion activity in LASV G1G2 hybrids. In keeping with 
our previous finding that replacing E17 with alanine did not disrupt membrane fusion 
activity (York and Nunberg, 2006), we propose that TM1 spans P12 to K33 to form a 
functional transmembrane subdomain in SSP.  
The above results also suggest that the extreme N terminus of SSP, comprising a 
myristoylation motif (GxxxS/T) and residues through I11, is interchangeable between 
JUNV and LASV. Indeed, alanine-scanning mutagenesis in this region of LCMV SSP 
showed only minimal effects on fusogenicity (Saunders et al., 2007). The amino acid 
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sequence of the cytoplasmic portion of region 1 appears relatively unimportant for 
membrane fusion activity. By contrast, the lack of myristoylation in SSP reduces 
fusogenicity by ∼80% through an unknown mechanism (Saunders et al., 2007; York et 
al., 2004) .  
Genetic analysis of the extended TM1. Site-directed mutagenesis was used to probe the 
extended TM1 helix in JUNV SSP. We reasoned that deletion of a single amino acid 
residue would alter the register of the helix without disrupting the overall helical fold 
(Agnihothram et al., 2007). A JUNV GPC mutant bearing a deletion at TM1 residue A25 
was found to be devoid of membrane fusion activity (figure 13C), consistent with a 
requirement for specific interhelical interactions within the GPC complex. Replacing 
hydrophobic amino acids with arginines in a membrane-spanning region is expected to be 
highly destabilizing, and the F14R and A25R mutants were indeed defective in 
membrane fusion (figure 13C). The deficiency in F14R supports our previous suggestion 
that SSP enters the membrane at P12. Neither the deletion nor arginine replacement 
mutants associated with the G1G2 precursor (not shown). Taken together, these results 
point to the critical importance of the extended TM1 helix in GPC biology.  
Owing to the helix-breaking property of proline, TM1 is unlikely to include 
residues N terminal to the conserved P12. To determine whether P12 itself is essential for 
GPC assembly and fusogenicity, we mutated this position in JUNV SSP to alanine. The 
P12A mutant was found to possess wild-type fusion activity (figure 13C). The identical 
mutant in LCMV SSP also showed significant fusion activity (∼30% of the wild type) 
but did not promote entry by recombinant virus-like particles  (Saunders et al., 2007) . 
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Thus, a proline-dependent articulation between the cytosolic N terminus and TM1 is not 
required for fusogenicity per se.  
TM1 forms an amphipathic helix.  A helical-wheel projection diagram reveals distinct 
hydrophobic and hydrophilic faces to the extended TM1 helices in JUNV and LASV 
SSPs  (figure 16).   By contrast, TM2 of SSP (K40/T40 to G54) is uniformly 
hydrophobic. As TM2 was found to be highly tolerant of triplet-alanine substitutions 
(Agnihothram et al., 2007), we employed a similar strategy to examine the requirement 
for side chain-specific interactions in TM1. We replaced three hydrophobic sequences in 
TM1 of JUNV SSP (13TFL15, 22ALV24, and 29IAI31) with triplet alanines, a small 
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residue with high helical propensity. Alanine substitutions at 13TFL15 and 22ALV24 
were found to disrupt membrane fusion activity (figure 13C). Fusogenicity was 
unaffected by alanine replacements at 29IAI31, probably due to its position in the helix 
and the conservative nature of the change. The defect in the 13TFL15 and 22ALV24 
mutants strongly suggests that TM1 participates in side chain-specific interactions in the 
GPC complex, likely with the transmembrane helical domain of G2.  
To probe the contributions of specific side chains in TM1 to these interactions, we 
individually replaced each polar residue on the hydrophilic face of TM1 with alanine  
(figure 13C) . T13A, Q16A, and S27A GPCs were essentially wild type in cell-cell fusion 
activity, as was E17A (Agnihothram et al., 2007). The N20A mutation, however, 
decreased membrane fusion activity to ∼30% of the wild type  (figure 13C) , as did the 
identical mutant in LCMV GPC  (Saunders et al., 2007). Interestingly, structural 
predictions by the Robetta server (http://robetta.bakerlab.org) (Kim et al., 2004) 
consistently position N20 at a kink in the TM1 helix (not shown).  
SSP chimeras differ in sensitivity to small-molecule fusion inhibitors.  We have 
previously shown that both pH-dependent activation and its inhibition by small-molecule 
fusion inhibitors are mediated through interactions between SSP and the G2 fusion 
subunit (York and Nunberg, 2006, 2009; York et al., 2008)). We therefore examined the 
sensitivity of hybrid GPCs to inhibition by the four chemically distinct fusion inhibitors 
discovered by SIGA Technologies (Corvallis, OR) (Bolken et al., 2006; Larson et al., 
2008; Thomas et al., 2011; York et al., 2008).  These compounds share a binding site 
(Thomas et al., 2011) but differ in their specificity toward NW and OW arenaviruses: ST-
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294 and ST-761 are active only against NW viruses, ST-161 is specific for LASV, and 
ST-193 is broadly inhibitory against both OW and NW arenaviruses (Bolken et al., 2006; 
Larson et al., 2008; Thomas et al., 2011; York et al., 2008).  
As hybrid GPCs heterotypic in SSP region 1 are nonfunctional, we focused our 
attention on the ectodomain loop, a region previously shown to affect inhibition (York et 
al., 2008). Substitution of the JUNV ectodomain loop in LASV GPCs [LJJ and (JexL)JL] 
abrogated inhibition by the LASV-active compounds ST-161 and ST-193 (not shown). In 
contrast, replacement of the ectodomain loop in JUNV GPCs (JLL, JLJ) showed no 
significant effects on sensitivity; all were inhibited by ST-294, ST-761, and ST-193 and 
resistant to ST-161 (not shown). Structural differences at the hybrid inhibitor-binding site 
likely contribute to the differing contributions of the heterotypic SSP ectodomain in 
LASV and JUNV GPC. None of the hybrids displayed de novo sensitivity to inhibition.  
We utilized the panel of alanine mutations in JUNV TM1 to further identify 
specific side chains that may influence sensitivity to inhibition. The triplet-alanine mutant 
(the 29IAI31 mutant), with substitutions adjacent to the SSP ectodomain and the critical 
K33 residue, was found to be unchanged in its sensitivity to ST-294 and ST-193 and 
resistance to ST-161 (figure 17 and table 2).  Similarly, individual alanine mutations at 
Q16, E17, and S27 on the hydrophilic face of TM1 did not significantly alter the pattern 
of inhibition. By contrast, alanine substitutions toward the cytosolic terminus of TM1 
(P12A and T13A) engendered resistance to ST-193 without qualitative or quantitative 
changes in the effects of ST-294, ST-761, or ST-161 (figure 17 and table 2).  
Furthermore, the N20A mutant was now strikingly dependent on ST-193 for wild-type 
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fusion activity. Fusion was enhanced by the addition of ST-193 in a dose-dependent 
manner. Maximal activity approaches that of the wild-type JUNV GPC at ∼10 μM ST-
193, at which point inhibitory and/or cytotoxic effects may intervene. Sensitivities to ST-
294 and ST-161 remain unaffected. The diversity in the effects of these different amino 
acid substitutions highlights the multiplicity of determinants for fusion inhibition within 
the GPC complex (York and Nunberg, 2009; York et al., 2008).  
We suggest that ST-193 binding to N20A compensates for structural changes 
induced by the mutation, thereby facilitating on-path conformational changes during pH-
induced activation of membrane fusion. Mutations in G2 previously reported to increase 
the pH of activation in the K33Q mutant to wild type without themselves affecting pH 
sensitivity may act similarly (York and Nunberg, 2009). Among these compensatory G2 
mutations, two (D400A and F427A) also engender resistance to ST-193 and ST-294 
((York et al., 2008) and unpublished data). Based on the dependence of the N20A mutant 
on the presence of inhibitor, we infer that resistance at the two G2 positions, as well as 
that in P12A and T13A SSP mutants, may reflect a balance of inhibitory and 







Our previous studies have shown that the short ectodomain loop of SSP and its 
interactions with G2 are important determinants for both pH-dependent membrane fusion 
and its inhibition by small-molecule compounds (York and Nunberg, 2006; York et al., 
2008). The present study identifies the critical role of the first membrane-spanning 
domain of SSP in these events. By characterizing a series of SSP chimeras containing 
JUNV and LASV sequences, we demonstrate that a homotypic pairing between TM1 and 
G2 is required for GPC-mediated membrane fusion. We propose that multiple 
intersubunit contacts between these transmembrane helices serve to position the critical 
K33 side chain in the SSP ectodomain for pH-sensitive interactions with the G2 
ectodomain. Small-molecule compounds that stabilize these interactions in the prefusion 
GPC complex have been shown to prevent pH-induced fusion activation in the endosome 
and thereby inhibit arenavirus entry. Detailed knowledge of the atomic interactions 
between SSP and G2 in the membrane-anchored GPC trimer will be important for 
understanding the mechanism of pH-dependent membrane fusion and guiding the design 
of potent and broadly active small-molecule fusion inhibitors.  
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Chapter 4: Engineering of a Potential Model for Transmembrane Interactions 




 Mutational analysis and fusion inhibition studies have illustrated the dependence 
of pH-mediated fusion on the interaction between SSP and G2.  While several key 
residues in the pH-sensitive interface are in the membrane proximal and extracellular 
domains, residues within the TM domains have also been shown to alter fusion activity 
(F427A, A435I, F438I, W428A in G2 and N20A in SSP) and drug sensitivity (F427A in 
G2 and P12A, T13A, and N20A in SSP) (Messina et al., 2012; York and Nunberg, 2009; 
York et al., 2008).  In contrast to the second TM region of SSP (TM2), which has been 
shown to be resilient to alanine mutations and uniformly hydrophobic (Agnihothram et 
al., 2007), side-chain specific interactions within the N-terminal TM region of SSP 
(TM1) are important for fusion activity and both the TM domain in G2 and TM1 are 
predicted to be amphipathic helices.  Therefore, we hypothesize that TM1 and the TM 
region of G2 interact with each other within the trimeric GPC.  We propose that the polar 
faces of the TM domains will be buried, interacting with each other, and the hydrophobic 
faces will be presented outward to interact with the hydrophobic membrane.  
To pursue this hypothesis, I engineered a novel TM construct, termed TMCON, 
which might serve as a model for the potential interactions between the TM domains.  
TMCON is comprised of the first 34 residues of SSP connected to a FLAG tag, which is 
flanked by short linker regions, and then connected to the terminal 70 residues of G2 
(figure 18).  I also created two more constructs, with the S-peptide tag (spep) on the N- or 
C-terminus, respectively. The objective of this work is to express, purify, and perform 
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preliminary biochemical and in vitro characterizations of the construct.  
 
B. Methods 
Cloning. pcDNA3.1 TMCON was created using the primers GC-SSPTM1-G2TM and 
SSPTM1-G2TM (table 3), with the Junin GPC-spep plasmid as a template, in the 
QuikChange II XL Site-Directed Mutagenesis (Agilent 200521).  To express TMCON in 
insect cells, the TMCON open reading frame transferred into the pDEST8 plasmid using 
the Gateway System (Invitrogen) two-step protocol. 
 
Membrane preparations. Hi5 cell pellets were thawed in cold TMNZ buffer (25mM 
Tris pH 7.6, 5mM MgCl2, 250mM NaCl, 100 µM ZnSO4, plus protease inhibitors (1 μg 
[each] of aprotinin, leupeptin, and pepstatin/ml). All subsequent steps are performed at 
4
o
.  Nitrogen decompression (1000 PSI in a Parr Bomb for 60 min) was used to disrupt 
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cells, which were then spun at 3,000 RPM for 10 min to remove cellular debris. 
Membranes were then isolated from the supernatant by ultracentrifugation at 100,000 × g 
for 1 h. The pellet was resuspended by dounce homogenization in TMNZ buffer and the 
high speed spin was repeated.  The pellet was then dounced again in TMNZ buffer with 
detergent (either 3% DDM or 10% sarkosyl) and then allowed to solubilize with mild 
agitation for either 2 hrs or overnight. A final 1hr 100,000 × g spin was performed and 
both the pellet and supernatant are saved to analyze the detergent insoluble (pellet) and 
soluble fractions (supernatant).  
 The lipids, palmitoyloleoyl phosphatidylcholine, palmitoyloleoyl 
phosphatidylethanol, and palmitoyloleoyl phosphatidylglycerol (POPC, POPE, and 
POPG, respectively) were used as a mixture at a ratio of 3:1:1 to improve purification 
efficiency from FLAG-resin (Sigma A2220).  
Size Exclusion Chromatography (SEC).  DDM soluble protein was allowed bind to 
FLAG-affinity resin for 2 or more hours. The resin was subsequently washed twice with 
TMNZ containing 1% DDM and 1 time with TMNZ buffer containing 0.1% DDM.   
TMCON was then eluted with 5 μM of 3×FLAG peptide in (Sigma F4799). The eluate 
was subjected to SEC using a Superdex-200/G-75 tandem column (GE) to purify 
TMCON and determine its oligomeric state. SEC buffer contained 0.05% DDM.  
Molecular weight sizes were determined by comparison to the elution profile of the Gel 




Co-immunoprecipitation. BSR cells were transfected as described in chapter 3.  Cells 
were harvested in cold PBS, and suspended in TX-100 lysis buffer (50 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 1% Triton X-100, and protease inhibitors).  Lysates were cleared by 
centrifugation at 14,000RPM, 4
o
, 15 min, and then supernatants were incubated for 2 hrs, 
with rocking, at 4
o
, with 1µL BF11 (1mg/ml) and 50µL protein-A sepharose beads.  After 
washing, samples were heated in 2X LDS (Invitrogen) with reducing agent at 70
o
, run on 
pre-cast 4-12% Bis-Tris polyacrylamide gels (Invitrogen), and transferred to PVDF 
membranes.  The blots were probed sequentially with the monoclonal anti-spep mouse 
IgG antibody (Pierce MA1-981) at a 1:1000 dilution for 60 min, and then the secondary 
horseradish peroxidase tagged goat anti-mouse.  
 
Crosslinking. SEC purified TMCON was dialyzed into 10mM HEPES plus .05% DDM 
to remove the Tris.  The Bis(sulfosuccinimidyl)suberate (BS
3
, Pierce 21585) crosslinking 
agent is an amine-reactive crosslinker with an 8-carbon spacer arm.  To crosslink 
TMCON, 2 µL of BS
3
 was added to 32µL of dialyzed TMCON.  The reaction was then 
vortexed and incubated on ice for 2 hrs. The reaction was quenched by adding 2µL 1M 
Tris pH 7.5.  Samples were then run on reducing SDS-PAGE gels and analyzed by 
Western blotting as described above.   
 
Confocal Microscopy. Transiently transfected BSR cells were re-seeded into 4-chamber 
glass bottom dishes (Greiner 627870), 80,000 cells per chamber, 16 hrs post-transfection.  
12 hrs later, cells were washed 3 times with RT PBS and then fixed for 45 min at RT with 
ice-cold and freshly prepared 4% Paraformaldehyde (PFA).  Next, cells were treated with 
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50mM Tris for 20 min then and permeabilized with 0.2% TX-100 in PBS for 10 min.   
Cells were blocked for 20 min and then probed for 90 min with primary antibody (Golgi 
specific α-GM130 (abcam  at 1:250, TMCON-spep specific α-spep at 1:250, or α-G1 
MAB BE08 at 1:500) in block solution (5% BSA in 0.1% TX-100 PBS). Chambers were 
washed 5 times with block solution and then cells were incubated with the secondary, 
GAM-568 or GAR- 488, at a 1:800 dilution for 90 min. After washing five times, cells 
were treated with SlowFade Gold with DAPI (Invitrogen S36938) and examined using an 
Olympus Fluoview 1000 laser scanning confocal microscope.  
 
Flow cytometry.  Cells were transfected with TMCON-spep plasmid alone or with 
wtJGPC plasmid, or salmon sperm DNA as a negative control, harvested 24hrs later, 
washed and resuspended in PBS, and stained with either anti-FLAG, anti-spep, or BE08 
Ab (all used at 1:50) for 45 min on ice. Cells were then washed and probed with a 
secondary fluorescein isothiocyanate (FITC)-labeled anti-mouse antibody. The cell 
populations were then stained with propidium iodine to exclude dead cells, fixed with 




Develop a Purification Scheme for TMCON expressed in Insect Cells. Our laboratory 
has an established protocol for the purification of JGPC from Hi5 cells using DDM to 
solubilize JGPC as a soluble trimer (Thomas et al., 2011, 2012).   My initial attempts to 
purify TMCON using this protocol resulted in a large portion of the protein in a 
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remaining in the detergent-insoluble pellet (figure 19).  I examined several conditions to 
solubilize the peptide.  TMCON is not readily soluble in acetic acid, methanol, DDM, or 
TX-100.  TMCON can be solubilized in GnHCl, Urea, SDS, and sarkosyl.  Sarkosyl has 
been used to efficiently solubilize proteins in a native form from inclusion bodies in E. 
coli (Francis et al., 2012; Tao et al., 2010).   Following the strategy from Tao et al, I 
solubilized the isolated membrane fraction in 10% sarkosyl overnight.  To affinity purify 
TMCON using FLAG-affinity beads, I diluted the sarkosyl solution with TX-100 and 
CHAPS to a final concentration 1% sarkosyl, 2% TX-100 and 20mM CHAPS.  This 
creates mixed micelles which prevents the sarkosyl from interfering with the interaction 
between the anti-FLAG MAB and the FLAG tag.  The diluted protein was applied to a 
FLAG-affinity column, washed once with 1% sarkosyl, 2% TX-100, and 20mM CHAPS, 
washed a second time with 1% sarkosyl, and then eluted with 3X-FLAG peptide.  With 
this protocol, I was able to purify TMCON, but I required excessively high 
concentrations of the 3X-FLAG peptide to elute the construct (up to four times the 
recommended 100 µg/ml recommended by Sigma).   To improve solubility and elution 
efficiency, I added a 0.1mg/ml mixture of lipids to all detergent containing buffers, which 
allowed efficient elution from the FLAG-resin with 100 µg/ml 3X-FLAG peptide (figure 
19). Purified TMCON remained soluble in sarkosyl + lipid solutions with as little as 






TMCON can form trimers.  To determine the oligomeric state TMCON, we analyzed 
the DDM-soluble fraction of the membrane prep by SEC.  Most of TMCON elutes as 
aggregates.  However, some TMCON elutes in a minor peak consistent in size with a 
dimer or trimer (figure 20).  To further study this fraction, we treated it the crosslinker, 
BS
3




TMCON from this 
peak undergoes specific crosslinking, as shown in figure 20.  In a dose dependent 
fashion, TMCON forms specific crosslinked species consistent in size with a timer and a 




TMCON associates weakly with JGPC.   We next asked if TMCON can associate 
with Junín GPC (JGPC) in vitro.  If TMCON is well-folded, we reasoned it may form 
mixed trimers with JGPC and perhaps traffic through the cell in a similar fashion to 
JGPC.  To determine if TMCON can associate with JGPC, I expressed TMCON alone or 
with JGPC in mammalian BSRT7/5 cells and then performed a co-immunoprecipitation 
with the G1 specific MAB, BF11, to pull-down JGPC and any associated TMCON.  I 
was able to reproducibly detect a faint TMCON-spep band that co-precipitated with GPC 
(figure 21E).  To determine if TMCON could traffic properly through the cell, I 
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performed confocal microscopy experiments to determine the intracellular localization of 
TMCON with and without co-expression of JGPC.  Previous work in our laboratory has 
demonstrated that wt-JGPC traffics through the cell from the ER to the Golgi, and then to 
the cell surface.  The cytosolic region of G2 contains two dibasic sequences which serve 
as ER-retention/retrieval signals.  Co-expression of SSP with G1/G2 is essential to 
masking these dibasic ER-retention sequences for transport.  However, removal of these 
sequences relieves G2 of its dependence on SSP for proper trafficking  (Agnihothram et 
al., 2006).  Expressed alone, TMCON aggregated as large puncta in the cell.  When co-
expressed with JGPC, TMCON was found more diffusely in the cell and in the Golgi 
apparatus.  We next asked if mutating the ER-retention signals in TMCON would affect 
its intracellular localization.  When I expressed the mutant TMCON KK/RR, which 
contains alanine substitutions in place of the dibasic sequences, this construct was found 
throughout the cytosol and in the Golgi.  However, expressed alone or with wtJGPC, 
neither TMCON nor TMCON KK/RR was detectable on the surface of healthy cells by 
surface staining and confocal microscopy.  This result was confirmed by flow cytometry.  
Because TMCON could insert into the membrane in a variety of orientations with one or 
both of the TM domains crossing the membrane, we used both α-spep and α-FLAG to 
detect possible cell surface expression, but we saw no significant population of cells 




D. Discussion  
TMCON contains the first TM region of SSP and the C-terminal 70 residues of 
G2, which includes both the TM region and cytosolic region.  Expressed alone, TMCON 
appears to be excluded from the Golgi and remains in the cytosol as large puncta, 
suggesting misfolding and aggregation of the construct.  Notably, removing the ER-
retention signals does alter its intracellular localization, indicating that the G2 region 
within TMCON does behave in a similar fashion to wtJGPC.  Pulldown experiments 
further demonstrate that TMCON can interact with JGPC.  Though this interaction may 
not be robust, the fact that co-expression of the two proteins changes the trafficking of 
TMCON indicates the interaction is functional.  These data, combined with the 
observation that TMCON can form trimers, suggest that the construct might capture 
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elements of the inter-helical interactions within the trimer. 
 With a purification protocol in place, TMCON can be produced and purified in 
large quantities, which will ease future biochemical studies.  Further characterization to 
determine if it is a suitable model for studying the interactions between the TM domains 
will be required.  Limited proteolysis experiments may be performed to identify a stable 
protease resistant core (Blacklow et al., 1995; Lu et al., 1995).  To determine the structure 
and orientation of TMCON in a membrane, protease protection assays in the presence 
and absence of liposomes can be done to determine which residues are protected and 
which are accessible to proteolysis. The resulting peptide fragments could be analyzed 
using silver-stained gels, mass spectrometry, and protein sequencing. If TMCON is well 
folded, it may be a suitable candidate for future structural studies such as electron 
paramagnetic resonance (EPR) (Mchaourab et al., 2011) or X-ray crystallization.   
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Chapter 5: Cysteine Scanning Mutagenesis and Crosslinking within the G2 
Transmembrane Domain 
A. Introduction 
GPC, like other class-I fusion proteins, takes the form of a trimeric spike on the 
viral envelope.  The “head” of the spike is comprised of the receptor binding subunit (in 
our case, G1) and the subunit that contains the fusion peptide and spans the membrane (in 
GPC, this is G2) forms the “stalk” (figure 2 and figure 5).  Studies detailing the 
arrangement of other class-I fusion proteins reveal that the “stalk” forms a tightly 
associated trimer and that the TM domain is important to fusion (Bissonnette et al., 
2009a; Chang et al., 2008; Kemble et al., 1994; Lamb and Jardetzky, 2007; Smith et al., 
2012; Weissenhorn et al., 2007).  Because site-directed mutagenesis has indicated that 
that specific residues within the TM domain of G2 and TM1 are important to fusion and 
drug sensitivity (Messina et al., 2012; York and Nunberg, 2009; York et al., 2008), we 
reasoned that the specific packing interactions between these TM domains are important 
to the overall geometry and function of GPC.  We hypothesized that the first TM region 
of SSP and the TM region of G2 interact with each other within the trimeric complex.  
We predict the G2 forms a tight trimer through the TM domain which is surrounded by 
the SSP TM domains (figure 22).  However, GPC is unique in its retention of SSP in the 
mature complex and other arrangements are possible. To determine the orientation of 
these TM domains to each other, I used a cysteine-scanning mutagenesis and disulfide 
crosslinking approach as described below. This strategy has proven very useful in 
probing the structures of several other membrane proteins and the class-I paramyxovirus 
F protein (Amin et al., 2006; Bissonnette et al., 2009a; Hamdan et al., 2002; Lee et al., 
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2006; Loo et al., 2004; Schwem and 
Fillingame, 2006; Winston et al., 2005).   
I created a library of single 
cysteine mutations spanning the entire 
TM of G2 (between residues proline-
419 and proline-445). The wt-G2 
contains one cysteine within its TM, so 
I used the TM cys-less background 
mutant C426S (which mediates wt-level 
fusion) for this mutational analysis. In 
each mutant GPC trimer, there will be 
three cysteines in the TM available for 
crosslinking.  We predicted that if they 
are oriented towards each other, and are 
within bonding distance, two will form a disulfide bond (and one will remain unbound) 
when exposed to a membrane soluble oxidant, such as I2 (Bass et al., 2007) or 
Cu(II)(1,10-phenanthroline)3 (Bissonnette et al., 2009).  If, on the other hand, they are not 
facing each other, they will not readily form a disulfide bond.  Thus, under non-reducing 
conditions on a SDS-PAGE gel, we should be able to readily distinguish a significant 
shift in the population of G2 monomers to dimers.  In this fashion, we hoped to map 
which face(s) of the G2 TM region may be interacting with each other and which may be 
free to interact with SSP.  
I first characterized this library of mutants by examining fusion activity.  I then 
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attempted to crosslink G2:G2 and G2:SSP cysteine pairs using multiple crosslinking 
agents under a variety of conditions.  Unfortunately, I was unable to detect any specific 
crosslinking under the conditions tested.   
B. Methods 
Cysteine mutants. Individual cysteine substitutions were made in G2 residues from P419 
to P445 in the pcDNA3.1 CD4-Adapt C426S-spep plasmid.  In other work, cysteine 
substitutions were also made in the pcDNA3.1 SSP plasmid to change residues T13, E17, 
and N20.  All substitutions were made using the QuikChange Lightning Multi Site-
Directed Mutagenesis Kit (Agilent 210516).  Primers used are listed in table 3. Cycling 
conditions were as follows: 95
o
 for 2 min, 30 cycles (95
o
 for 20 sec, 55
o
 for 30 sec, 65
o
 
for 4 min), 65
o
 for 5 min, hold at 4
o
.  Cysteine mutants within the TM region of the fusion 
subunit (F) of  the Paramyxovirus glycoprotein were kindly provided by Dr. Robert Lamb 
at Northwestern University (Bissonnette et al., 2009a) and used as positive controls. 
Protein expression, processing and detection.  Junin proteins were expressed in 
BSRT7/5 cells (described in chapter 3) and the paramyxovirus F proteins were expressed 
in 293 cells by transient transfection.   6µg of G1G2 and 2µg of SSP plasmid were 
transfected into a 6well cluster plate seeded with 450,000 cells using 25µL 
lipofectamine2000 (Invitrogen). Starting at 6 hrs post-transfection, cells were 
metabolically labeled using 
35
S-labeled amino acids (GE) overnight. 293 cells were 
transfected using the manufacturer recommend amounts of DNA and lipofectamine2000.  
18hrs post transfection, 293 cells were metabolically starved for 1 hour and then 
35
S-
labeled for 2 hours per the Lamb’s laboratory protocol (Bissonnette et al., 2009a). 
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 For oxidative crosslinking in membranes, cells were dounce homogenized (50 
strokes) in RSB buffer (10mM Tris pH 7.5, 10mM KCl, 15mM MgCl2 plus protease 
inhibitors). Homogenates were then treated with CuP, I2, or mock treated with equal 
volumes 50mM Tris pH7.5 or ethanol, respectively.  Specific crosslinking conditions are 
discussed in the Results and Discussion section below.  Reactions were quenched with 
10mM EDTA alone or with an additional 10mM NEM and 100mM IAM for 10 min at 
RT. Samples were then solubilized with an equal volume 2X lysis buffer.  Bissonette et al 
utilize 2X RIPA buffer (50mM Tris pH 7.5, 1mM EDTA, 150mM NaCl, 2% NP40, 0.2% 
sodium deoxycholate, 0.2% SDS plus protease inhibitors) (Bissonnette et al., 2009a) 
whereas our established IP protocol uses a TX-100 lysis buffer described above (1% TX-
100 final).  Solubilized samples were then spun at maximum speed in a microcentrifuge 
for 15 min.  Cleared supernatants were then immuno-precipitated with 1µL of the anti-G1 
MAB BF11 or 10µL of the paramyxovirus F protein specific polycolonal α-F2 (kindly 
provided by Robert Lamb). For the crosslinking of solubilized protein, cells were 
harvested in cold PBS, spun at 1500 RPM for 10 min, and then resuspended in 1ml TX-
100 lysis buffer.  Lysates were cleared, treated with crosslinker (I2 or CuP), and then 
quenched and immunoprecipitated as described above.  Buffers used during oxidative 
crosslinking of GPC samples also contained 50µM zinc to maintain the intersubunit zinc-
binding domain (Briknarová et al., 2011).                           
 For non-oxidative crosslinking experiments in membranes with 
bis(maleimido)ethane (BMOE, Pierce 22323), a bifunctional maleimide crosslinker with 
an 8Å linker arm, cells were dounce homogenized (50 strokes) in hypotonic lysis buffer 
(0.1X PBS) with  protease inhibitors. Homogenates were then spun at maximum speed in 
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the microcentrifuge for 15 min at 4
o
.  Pelleted membranes were then resuspended in 1X 
PBS plus protease inhibitors and either treated with BMOE or mock-treated with an equal 
volume of DMSO.  Crosslinking conditions are discussed in the following section.  After 
crosslinking, reactions were quenched with DTT (10mM final) for 15min at RT.  
Samples were then diluted 5 fold in 1.2X TX-100 lysis buffer (final 1% TX100) and 
immunoprecipitated with the α-G1 antibody, BF11.   
After immunoprecipitation, samples are heated to 90
o
 for 20 min in 4X LDS 
buffer (Invitrogen) with or without reducing agent and subsequently resolved on 4-12% 
Bis-Tris pre-cast polyacrylamide gels (Invitrogen), which were subsequently fixed, dried, 
and proteins were visualized by phosphorimaging with a Fuji FLA-3000G instrument.  
 Fusion assays were performed as described in chapter 3.  
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 C. Results and Discussion 
TM Cysteine Substitutions are well tolerated.  The nominal N-terminal junction of the 
G2 TM is at the charged D424.  Structural prediction programs (Roy et al., 2010)  
suggest the TM of G2 extends from L420 to L441 or I444.  I extended our cysteine-
scanning analysis from P419 to P445 to ensure complete coverage of the G2 TM.  We 
also created three cysteine substitutions in SSP: T13C, E17C, and N20C.  These residues 
are all predicted to be on the same helical face of the first TM domain and alanine 
substitutions at these residues were shown to alter drug sensitivity (Messina et al., 2012).   
Each of the G2 mutants was assessed biochemically for association between G2 and SSP 
77 
by radio-IP and for cell-cell fusion activity.  SSP association and cleavage of G1-G2 was 
observed in all cases.  Figure 23C,D shows an example of these data.  A subset of the 
mutation panel biochemical data is shown in figure 23C.  All of the mutants displayed 
greater fusion activity than the negative (no SSP) control and, with few exceptions 
(P419C, L420C, L422C), all demonstrated greater than 25% activity (figure 23A, B).    
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Looking at the fusion assay data we observed some degree of periodicity, 
particularly between residues V431 and P445 (figure 23A). The rise and fall of fusion 
activity about every 4 residues may be consistent with an important α-helical interface.  
These data also indicate that the cysteine mutations were not disruptive to the structure of 
GPC, and thus we hypothesized that a specific pattern of crosslinking would reveal the 
G2 TM domain to have a G2:G2 interacting face and a G2:SSP face. 
 
 Crosslinking Conditions.  I attempted to oxidatively crosslink G2 in dounced 
homogenates using CuP and I2.  I searched the literature to define the ranges of 
conditions used for oxidative crosslinking within membrane proteins (Hamdan et al., 
2002; Loo et al., 2004; Ma et al., 2004; Miller et al., 2003).  I then proceeded to test a 





), and reaction times (5 min to 1hr for CuP and 30 sec to 5m for 
I2) with my samples.  The primary stumbling block was in finding a set of conditions 
which did not result in a loss of GPC protein.  At high concentrations of crosslinking 
agent, GPC precipitated out of solution and I saw a significant loss in signal.  Longer 
reaction times and crosslinking at 37
o
 caused excessive background crosslinking and 
higher order aggregates such that proteins did not enter the gel. After lengthy 
troubleshooting, the conditions which worked best for preserving signal and reducing 
background were to treat dounced homogenized cells with 25µM CuP for 20m at RT.  
However, under these conditions, I detected no specific crosslinking between G2 or SSP 
mutants.  
As crosslinking maybe inefficient in the membrane and given that our laboratory 
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has an established protocol for immunoprecipitating solubilized GPC (Agnihothram et 
al., 2006; York et al., 2004, 2005), I also attempted crosslinking in TX-100 solubilized 
samples over a similar range of conditions listed above.  However, excessive background 
crosslinking and protein precipitation (figure 24C) again proved to be problematic.  After 
examining the same range in crosslinker concentration, temperature, and timing as 
described above, I established a protocol of crosslinking for 10m at RT using 25µM CuP 
(figure 24D).  To verify this protocol with a positive control, we obtained paramyxovirus 
F protein samples from Dr. Robert Lamb’s laboratory (Bissonnette et al., 2009).  Using 
both their published protocol (3mM CuP) and the one described above (25µM CuP), I 
was able to demonstrate strong and specific crosslinking at residue 506, but not 505, 
replicating their published results (figure 24 B,A respectively).  In this figure, one can 
observe a clear increase in the ratio of F dimers (about 55kDa) to monomers (about 100 
kDa) using both protocols.   However, I was not able to demonstrate any specific 
crosslinking with my G2 or SSP mutants using either protocol (figure 24 C, D).  Under 
low CuP concentrations (25 µM), I do observe a band consistent in size (about 120 kDa) 
with an uncleaved G1G2 dimer (figure 24D).  However, I also see this band in untreated 
controls resolved under  non-reducing conditions (data not shown) and this band is seen 
consistently in all the G2 mutants without variation in the ratio of this potential dimer to 
the monomer.  Therefore, we have concluded this band is most likely background dimer 
formation.  A similar background level of dimer formation may be seen in the 
paramyxovirus F mutants (figure 24 A,B).  
To address the possibility that the G2 domains are not oriented symmetrically, I 
also tried crosslinking each G2 cysteine mutant with each of its four upstream and four 
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downstream neighboring residues.   This set of experiments also failed to yield any 
specific crosslinking. 
 
To address the possibility that the G2 helices maybe not be packed tightly enough 
for cysteine pairs to form a disulfide bond (2 Å), I used a bifunctional maleimide 
crosslinker with an 8Å linker arm, BMOE (Hamdan et al., 2002).  This non-oxidative 
crosslinker will form a covalent bond between two cysteine residues. I tried BMOE (0.02 
mM to 2.0mM) using both solubilized and dounce-homogenized samples at 4
o
, RT, and 
37
o
, over a range of reaction times (20 min to 120 min) without a positive result. 
We expected these crosslinking studies to show that the G2 TM domains associate 
with each other and with the TM1 (figure 22).  As the G2 TM is thought to be α-helical, 
we predicted a periodicity in disulfide bond forming which would allow us to determine 
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the inner and outer faces of the G2 TM domain (Bissonnette et al., 2009).  By extending 
our cysteine substitution library past the nominal borders of the TM domain and using a 
longer crosslinker, we hoped to account for the possibility that the TM domains may 
curve or tilt away from each other in such a way that only residues within a certain region 
of the helix are close enough form disulfide bonds (Alisio and Mueckler, 2004).  
However, as I was unable to demonstrate any specific G2:G2 or G2: SSP crosslinking 
similar to what we observed with the paramyxovirus controls, we were unable to 
elucidate the arrangement of the TM domains using this approach.   
Potential reasons for my negative results are manifold.  Despite the exhaustive 
search for appropriate crosslinking conditions, it is possible that I was unable to identify 
the specific reaction conditions necessary to induce crosslinking within GPC.  This 
hurdle may be related to the intersubunit zinc-binding domain (ZBD).  The zinc-
interacting cysteines may not be protected from crosslinking agents, even in the presence 
of excess zinc.  It is possible that at the concentrations of crosslinker needed to induce 
G2:G2 or G2:SSP dimers, the crosslinker is disrupting the ZBD, causing non-specific 
crosslinking or a collapse of the GPC trimer. It could also be that the helices are arranged 
in novel way so that the G2 domains are not facing each other or that the TM helices are 
spaced further apart and a crosslinker with a longer (than 8Å) arm is required.  
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Chapter 6: Conclusions and Future Directions 
 Arenaviruses continue to be a significant public health threat due to severity of 
illness caused and the lack of suitable treatments.  Therefore, the search continues for 
improved antiviral strategies and better understanding of arenavirus biology.  My 
dissertation research has centered on two important topics.  The first project, as detailed 
in chapter 2, addresses the question of how T-705 inhibits highly pathogenic 
arenaviruses.  Chapters 3-5 discuss the second thrust of my research that focuses on 
defining the inter-subunit interactions within GPC and how these interactions may affect 
fusion and drug sensitivity.  
Options for treating severe arenaviral hemorrhagic fever cases are limited to the 
off-label use of  ribavirin, which is known for its negative side effects, and transfer of 
immune plasma for JUNV patients (Borio et al., 2002; Chapman et al., 1999; Rusnak et 
al., 2009).  Thus, the development of alternative antivirals for use in arenaviral infection 
is critical.  T-705 has been shown to be an effective inhibitor of RNA viruses, but it had 
not been previously evaluated against highly pathogenic arenaviruses.  Studies in chapter 
two demonstrate for the first time that T-705 is effective at inhibiting the replication of 
highly pathogenic viruses in vitro.  Further, we show that T-705 works against these 
viruses in the middle of the viral life cycle and specifically inhibits viral transcription at 
concentrations similar to ribavirin. In contrast to ribavirin, T-705 showed very little 
reduction in cellular transcription activity, even at the highest doses tested.  These data 
indicate T-705 may have fewer off-target cellular effects and be a safe alternative to 
ribavirin for treatment of arenaviral infection. This study is an important step in the 
process of understanding how T-705 inhibits arenaviral replication and in the 
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development of T-705 for use as a treatment for arenaviral HF.  Our data are consistent 
with studies that show T-705 does not significantly inhibit IMPDH (Furuta et al., 2005) 
while ribavirin does (Graci and Cameron, 2006). It is known that T-705 RTP, likely acts 
as a purine analog against the influenza polymerase (Furuta et al., 2005).  Our data 
demonstrating that nearly all purine-based compounds showed a significant effect on T-
705 activity are consistent with this observation and suggest a conserved mechanism of 
action against viral RNA polymerases.  A  recent publication has shown that T-705 can 
be mutagenic in H1N1 influenza (Baranovich et al., 2013) serially passaged in tissue 
culture.  Interestingly, another very recent report demonstrates that T-705RTP can block 
nascent RNA chain elongation in crude RdRp preparations (Sangawa et al., 2013).  
Further studies will be needed to determine which of these mechanisms may be at play 
during arenavirus infection and to study the safety and efficacy of using T-705 to treat 
arenaviral infection in vivo.  Importantly, T-705 has completed phase 3 clinical trials in 
Japan and phase 2 clinical trials in the U.S. for the treatment of influenza infection. T-705 
was demonstrated to significantly reduce the symptoms of influenza infection and shorten 
the time to clear virus with an excellent safety record (DOD, 2013; in Furuta et al, 2013).  
Our studies and those done by others demonstrate that T-705 is effective against 
arenaviruses in tissue culture and in animal models (reviewed in Furuta et al, 2013).  
Taken together, T-705 is a very good candidate for further study in the treatment of 
arenaviral HF.  
Elucidating the detailed structure and function of GPC is critical to understanding 
and inhibiting membrane fusion.   Previous studies in our laboratory have shown that the 
interactions between the membrane proximal region of G2 and the extracellular loop of 
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SSP are key to the pH-sensitive triggering of fusion (York and Nunberg, 2009).  In 
chapter 3, I demonstrated a homotypic match between G2 and the ectodomain loop of 
SSP enhanced, but was not required, for fusion activity.  Instead, a match between G2 
and TM1 was shown to be necessary and sufficient for fusion competency. My work 
defined an essential sub-domain within SSP from residues P12-K33 and suggests that the 
TM domain begins at P12, not E17 as previously thought (Eichler et al., 2004).  I also 
show that this TM region is more sensitive to mutation than the second SSP TM domain 
(Agnihothram et al., 2007).  We further demonstrate that residues within this TM domain 
are key to drug sensitivity (T13, E17, N20).  These data reveal an important role for the 
first SSP TM region and indicate that sequence specific interactions with the G2 TM 
region are necessary for the proper geometry of GPC. 
This and previous work (York and Nunberg, 2009; York et al., 2008) 
demonstrating that some residues within the G2 TM domain are important for mediating 
fusion and drug sensitivity is consistent with the knowledge that the TM domains of 
class-I fusion proteins are more than simple membrane anchors (Kemble et al., 1994; 
Smith et al., 2012).  Studies show that in many of these TM domains, a degree of 
sequence specificity is required for fusion activity, that these domains are closely 
associated with each other (Bissonnette et al., 2009a; Chang et al., 2008; Smith et al., 
2012) and are important to protein folding and trimer formation (Smith et al., 2012).   
As GPC is unique among class-I fusion proteins in its retention of SSP, and given 
that the trimer has nine TM domains instead of three, it will have a unique arrangement 
of helices in the membrane.  By analogy to other class-I fusion proteins, we hypothesize 
that the G2 helices form a tight core that is closely associated with the SSP TM domains 
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(figure 22).  This arrangement seems likely because the G2 TM domain has clear 
hydrophilic and hydrophobic faces, as does SSP TM1. Additionally, side chain-specific 
interactions between the helices appear to be important for fusion and drug sensitivity.  
Further, we know that residues at the periphery of the membrane regions must be in close 
proximity to interact with each other (K33 in SSP with membrane proximal residues in 
G2) (Messina et al., 2012; York and Nunberg, 2009; York et al., 2008).  Given the 
difficulties inherent in crystallizing glycoproteins (Chasman, 2003; Forster et al., 2005; 
Shimizu et al., 2008), other approaches to elucidating the interactions within GPC should 
be explored.  I created a novel truncated construct, TMCON, to serve as a potential model 
for these TM interactions (chapter 4) and I attempted to map the arrangement of the TM 
domains within the GPC trimer using cysteine-scanning mutagenesis and crosslinking 
assays (chapter 5).   
Until the structure of the intact GPC complex can be determined, deciphering the 
structure of specific subdomains within GPC remains a valid approach.  I cloned and 
characterized the model construct, TMCON, to serve as a potential tool in this divide-
and-conquer approach to elucidating the relationship between the TM domains within 
GPC.  TMCON does not perform like wtJGPC, but it does retain some important 
functional properties, such as its ER-retention pattern and the abilities to form trimers and 
associate with wtJGPC.  Thus, this novel construct has the potential to be an informative 
model of the interactions between TM1 and the TM domain of G2.   However, additional 
questions regarding its structure and its interactions with membranes remain. For 
instance, I have shown that TMCON and wtJGPC can associated with each other, but the 
nature of this interaction is unclear.  We could examine the ability of wtJGPC to traffic 
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and mediate fusion when co-expressed with TMCON to determine if the interaction 
between these two proteins is detrimental to the functioning of wtJGPC.  Additionally, 
while I have demonstrated that TMCON is purified in membrane preps from insect cells, 
we may address the possibility that the construct maybe pelleted as aggregates by 
performing floatation assays.  We expect that these assays would show a significant 
portion of TMCON is membrane associated, as others have shown that insertion of Lassa 
GPC into the ER-membrane requires only one of the two SSP TM domains (Eichler et al, 
2004).  Further, assuming that TMCON is a bona-fide membrane-associated protein, it is 
essential to determine its topology in the membrane. To characterize the structure and 
orientation of TMCON in a membrane, protease protection assays in the presence and 
absence of liposomes can be done to determine which residues are protected and which 
are accessible to proteolysis. The resulting peptide fragments could be analyzed using 
silver-stained gels, mass spectrometry, and protein sequencing.  
 In chapter 5, I used a cysteine-scanning mutagenesis approach that has proven 
useful in mapping TM domains in other proteins (Amin et al., 2006; Bissonnette et al., 
2009a; Hamdan et al., 2002; Lee et al., 2006; Loo et al., 2004; Schwem and Fillingame, 
2006; Winston et al., 2005). However, as I was unable to achieve specific crosslinked 
products despite an exhaustive search of reaction conditions, we cannot make any 
definitive statements about the arrangement of the GPC TM domains.  It is possible that 
the G2 TM arrangement varies from the typical coiled central core, as has been suggested 
for Moloney murine leukemia virus (MoMuLV).  If the G2 TM domains are arranged in a 
similar fashion to the TM domains of the  MoMuLV glycoprotein, splayed  like a tripod 
(Forster et al., 2005; Löving et al., 2012), or are in a novel configuration  in which  the 
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TM domains are not tightly packed, they will not be amenable to crosslinking.  It is also 
possible that I was unable to find the reaction conditions that induce specific crosslinking 
and maintain the structural integrity of the GPC trimer.  Other crosslinking conditions, 
such as lysis buffer used, crosslinking in vivo, or using a longer crosslinker could be 
explored. Theoretically, if cysteine substitutions were made throughout all the TM 
domains in GPC, we could ascertain the TM organization of GPC even if the TM 
domains were not symmetrically arranged. However, this would be logistically 
unfeasible. Others in our laboratory are currently working to establish protocols for mass-
spectrometry (MS) analysis of GPC TM peptides.  If these studies are successful, another 
approach of using a heterobifunctional (sulfhydryl to non-specific) crosslinker may be 
informative.  Using a G2 cysteine mutant, we could perform a crosslinking reaction 
which would link the free cysteine nonspecifically to whichever TM domain(s) are 
nearby. After isolating crosslinked products on a gel, they could be analyzed using MS to 
narrow down the interacting domains within the TM region of GPC.  Other approaches to 
studying the structure of the TM region within GPC could include cryo-EM of viruses or 
virus-like particles (Forster et al., 2005; Zhang, et al, 2013) and EPR (Mchaourab et al., 
2011).   
Taken together, the works presented in this dissertation provide new insights into 
the action of T-705 arenaviral inhibition and the interactions within GPC, though much 
work remains to be done.  Absent any structural data of the TM domains, several 
important questions remain.  We do not know how the TM domains physically interact 
with each other nor do we know at which step(s) of the fusion process these interactions 
occur. Understanding the geometry within the TM region of GPC would be a great boon 
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to our knowledge of how SSP and G2 function together during fusion and may lead to 
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